A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Official Title: 
Study ID: [REMOVED]
Document  Date
: Clinical Study Protocol Version  7.0: 16 December 2021Cell Carcinoma (POD1UM-201) 
Incyte Corporation  Page 1 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630 CONFIDENTIAL  Clinical Study Protocol  
INCMGA  0012 -201 
A Phase 2 Study of INCMGA00012 in Participants With Metastatic 
Merkel Cell Carcinoma  (POD1UM -201) 
Product:  INCMGA00012  
IND Number:  139,[ADDRESS_97998] Number:  2018 -001627 -39 
Phase of Study : 2 
Sponsor:  Incyte Corporation  
1801 Augustine Cut -Off 
Wilmington, DE [ZIP_CODE]  
Original  Protocol  (Version 0) : 07 JUN 2018  
Amendment (Version) 1:  27 JUN 2018  
Amendment (Version) 2:  [ADDRESS_97999] 2018  
Amendment (Version) 3:  05 DEC 2018  
Amendment (Version) 4:  16 AUG 2019  
Amendment (Version) 5:  09 APR 2020  
Amendment (Version) 6:  [ADDRESS_98000] 2020  
Amendment (Version) 7:  [ADDRESS_98001] their origin in the Declaration of 
Helsinki and conducted in a dherence to the study Protocol , applicable  Good Clinical Practices , and applicable laws 
and country -specific regulations in which the study is being conducted . 
The information in this document is conf idential .  No part of this information may be duplicated, referenced, or 
transmitted in any form or by [CONTACT_61076] (electronic, mechanical, photocopy, recording, or otherwise) without prior 
written  consent . 

Incyte Corporation  Page 2 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  INVESTIGATOR 'S AGREEMENT  
I have read the INCMGA 0012 -201 Protocol Amendment 7 (Version 7 dated 16 DEC  2021 ) and 
agree to conduct the study as outlined .  I agree to maintain the confidentiality of all information 
received or developed in connection with this Protocol . 
 
 
   
(Printed Name [CONTACT_7919])    
   
   
(Signature [CONTACT_7919])   (Date)  
Incyte Corporation  Page [ADDRESS_98002] OF ABBREVIATION S ................................ ................................ ................................ .......... 9 
1. PROTOCOL SUMMARY  ................................ ................................ .......................... 12 
2. INTRODUCTION  ................................ ................................ ................................ ......19 
2.1. Background  ................................ ................................ ................................ ................. 19 
2.2. Study Rationale  ................................ ................................ ................................ ........... 20 
2.2.1.  Justification for Dose  ................................ ................................ ................................ ..20 
2.3. Benefit/Risk Assessment  ................................ ................................ ............................ 21 
2.3.1.  Benefit/Risk Assessment During the COVID -19 Pandemic  ................................ ......21 
3. OBJECTIVES AND ENDPO INTS  ................................ ................................ ............ 22 
4. STU DY DESIGN  ................................ ................................ ................................ .......24 
4.1. Overall Design  ................................ ................................ ................................ ............ 24 
4.2. Overall Study Duration  ................................ ................................ ............................... 25 
4.3. Study Termination  ................................ ................................ ................................ ......25 
4.3.1.  Data Monitoring Committee  ................................ ................................ ....................... 25 
5. STUDY POPULATION  ................................ ................................ ............................. 27 
5.1. Inclusion Criteria  ................................ ................................ ................................ ........ 27 
5.2. Exclusion Criteria  ................................ ................................ ................................ .......27 
5.3. Lifestyle Considerations  ................................ ................................ ............................. 30 
5.4. Screen Failures  ................................ ................................ ................................ ............ 30 
5.5. Replacement of Participants  ................................ ................................ ....................... 30 
6. STUDY TREATMENT  ................................ ................................ .............................. 31 
6.1. Study Treatment Administered  ................................ ................................ ................... 31 
6.2. Preparation, Handling, and Accountability  ................................ ................................ 31 
6.3. Measures to Minimize Bias:  Randomization and Blinding  ................................ .......32 
6.4. Study Treatment Compliance  ................................ ................................ ..................... 32 
6.5. Dose Modifications  ................................ ................................ ................................ .....32 
6.5.1.  Management of Suspected Infusion Reactions  ................................ ........................... 33 
6.5.2.  Procedures for Participants Exhibiting Immune -Related Adverse Events  ................. 34 
[IP_ADDRESS].  Immune -Mediated Pneumonitis  ................................ ................................ .................. 34 
[IP_ADDRESS].  Immune -Mediated Colitis/Enterocolitis/D iarrhea  ................................ ...................... 35 
[IP_ADDRESS].  Immune -Mediated Hepatitis  ................................ ................................ ....................... 35 
Incyte Corporation  Page 4 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  [IP_ADDRESS].  Immune -Mediated Endocrinopathies  ................................ ................................ .......... 36 
[IP_ADDRESS].  Immune -Mediated Nephritis and Renal Dysfunction  ................................ ................. 38 
[IP_ADDRESS].  Immune -Mediated Skin Reactions  ................................ ................................ ............. 38 
[IP_ADDRESS].  Immune -Mediated Myocarditis  ................................ ................................ .................. 39 
[IP_ADDRESS].  Immune -Mediated Nervous System Events  ................................ ............................... 40 
[IP_ADDRESS].  Other Immune -Mediated Adverse Events  ................................ ................................ ..40 
6.5.3.  Permanent Discontinuation of Study Drug Due to Toxicity  ................................ ......41 
6.6. Concomitant Medications and Procedures  ................................ ................................ .41 
6.6.1.  Permitted Medications and Procedures  ................................ ................................ ......41 
6.6.2.  Prohibited Medications and Procedures  ................................ ................................ .....41 
6.7. Treatment After the End of the Study  ................................ ................................ ......... 42 
7. DISCONTINUATION OF S TUDY TREATMENT AND P ARTICIPANT 
DISCONTINUATION/WITH DRAWAL  ................................ ................................ ..[ADDRESS_98003] to Follow -Up................................ ................................ ................................ .......44 
8. STUDY ASSESSMENTS AN D PROCEDURES  ................................ ...................... 45 
8.1. Administrative and General Procedures  ................................ ................................ .....45 
8.1.1.  Informed Consent Process  ................................ ................................ .......................... 45 
8.1.2.  Screening Procedures  ................................ ................................ ................................ ..46 
8.1.3.  Interactive Response Technology Procedure  ................................ .............................. 46 
8.1.4.  Distribution of Reminder Cards  ................................ ................................ .................. 46 
8.1.5.  Demography and Medical History  ................................ ................................ .............. 46 
[IP_ADDRESS].  Demographics and General Medical History  ................................ ............................. 46 
[IP_ADDRESS].  Disease Characteristics and Treatment History  ................................ .......................... 47 
8.2. Efficacy Assessments  ................................ ................................ ................................ .47 
8.2.1.  Tumor Imaging  ................................ ................................ ................................ ........... 47 
8.2.2.  Photographic Analysis of Skin Lesions  ................................ ................................ ......48 
 48 
8.2.4.  Health Economics  ................................ ................................ ................................ .......48 
 48 

Incyte Corporation  Page 5 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL   48 
 49 
8.3. Safety Assessments  ................................ ................................ ................................ .....49 
8.3.1.  Adverse Events  ................................ ................................ ................................ ........... 49 
8.3.2.  Physical Examinations  ................................ ................................ ................................ 50 
8.3.3. Vital Signs  ................................ ................................ ................................ .................. 50 
8.3.4.  Eastern Cooperative Oncology Group Performance Status  ................................ ........ 50 
8.3.5.  Electrocardiograms  ................................ ................................ ................................ .....51 
8.3.6.  Laboratory Assessments  ................................ ................................ ............................. 51 
[IP_ADDRESS]. Pregnancy Testing  ................................ ................................ ................................ ......52 
8.4. Pharmacokinetic Assessments  ................................ ................................ .................... 54 
 54 
 54 
 55 
 55 
8.6. Unscheduled Visits  ................................ ................................ ................................ .....56 
8.7. End o f Treatment and/or Early Termination  ................................ .............................. [ADDRESS_98004]-Treatment Disease Follow -Up ................................ ................................ ............ 57 
8.8.3.  Survival Follow -Up ................................ ................................ ................................ ....57 
9. ADVERSE EVENTS:  DEF INITIONS AND PROCEDU RES FOR 
RECORDING, EVALUATIN G, FOLLOW -UP, AND RE PORTING  ...................... 58 
9.1. Definition of Adverse Event  ................................ ................................ ....................... 58 
9.2. Definition of Serious Adverse Event  ................................ ................................ .......... 59 
9.3. Recording and Follow -Up of Adverse Events and/or Se rious Adverse Events  ......... [ADDRESS_98005] Complaints  ................................ ................................ ................................ ....65 
9.10.  Treatment of Overdose  ................................ ................................ ............................... 65 

Incyte Corporation  Page 6 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  10. STATISTICS  ................................ ................................ ................................ .............. 66 
10.1.  Sample Size Determination  ................................ ................................ ........................ 66 
10.2. Populations for Analysis  ................................ ................................ ............................. 66 
10.3.  Level of Significance  ................................ ................................ ................................ ..66 
10.4.  Statistical Analyses  ................................ ................................ ................................ .....67 
10.4.1 . Primary Analysis  ................................ ................................ ................................ ........ 67 
[IP_ADDRESS].  Overall Response Rate  ................................ ................................ ................................ 67 
[IP_ADDRESS].  Handling of Missing Data in Primary Analysis  ................................ .......................... 67 
10.4.2.  Secondary Analysis  ................................ ................................ ................................ ....67 
[IP_ADDRESS].  Duration of Response  ................................ ................................ ................................ .67 
[IP_ADDRESS].  Disease Control Rate  ................................ ................................ ................................ ..67 
[IP_ADDRESS].  Progression -Free Survival  ................................ ................................ .......................... 68 
[IP_ADDRESS].  Overall Survival  ................................ ................................ ................................ .......... 68 
10.4.3.  Safety Analyses  ................................ ................................ ................................ .......... 68 
[IP_ADDRESS].  Adverse Events  ................................ ................................ ................................ ........... 68 
[IP_ADDRESS].  Adverse Events of Special Interest  ................................ ................................ ............. 68 
[IP_ADDRESS].  Clinical Laboratory Tests  ................................ ................................ ........................... 68 
[IP_ADDRESS].  Vital Signs  ................................ ................................ ................................ .................. 69 
[IP_ADDRESS].  Electrocardiograms  ................................ ................................ ................................ .....69 
[IP_ADDRESS].  Dose Intensity  ................................ ................................ ................................ ............. [ADDRESS_98006] OF TABLES  
Table  1: Primary and Secondary Objectives and Endpoints  ................................ ..................... 12 
Table  2: Key Study Design Elements  ................................ ................................ ....................... 13 
Table  3: Schedule of Activities  ................................ ................................ ................................ .15 
Table  4: Pharmacokinetic  Sample Collections  ................................ ............ 17 
Table  5: Objectives and Endpoints  ................................ ................................ ........................... 22 
Table  6: Exclusionary Laboratory Values  ................................ ................................ ................ 28 
Table  7: Study Treatment Information  ................................ ................................ ..................... 31 
Table  8: Guidelines for Management of Suspected Infusion Reactions  ................................ ...33 
Table  9: Recommended Approach to Handling Pneumonitis  ................................ ................... 35 
Table  10: Recommended Approach for Handling Colitis/Enterocolitis/Diarrhea  ...................... 35 
Table  11: Recommended Approach for  Handling Hepatitis  ................................ ....................... 36 
Table  12: Recommended Approach for Handling Hypophysitis  ................................ ................ 37 
Table  13: Recommended Approach for Handling Thyroid Disorders  ................................ ........ 37 
Table  14: Recommended Approach for Handling New Onset Type 1 Diabetes 
Mellitus/Hyperglycemia  ................................ ................................ ............................. 38 
Table  15: Recommended Approach for Handling Adrenal Insufficiency  ................................ ..38 
Table  16: Recommended Approach for Handling Nephritis and Renal Dysfunction  ................ 38 
Table  17: Recommended Approach for Handling Skin Reactions  ................................ ............. 39 

Incyte Corporation  Page 8 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Table  18: Recommended Approach for Handling Myocarditis  ................................ .................. 39 
Table  19: Recommended Approach for Handling Immune -Mediated Nervous System 
Events  ................................ ................................ ................................ ......................... 40 
Table  20: Recommended Approach to Handling Other Immune -Mediated Adverse 
Events  ................................ ................................ ................................ ......................... 40 
Table  21: Eastern Cooperative Group Performance Status Scoring  ................................ ........... 50 
Table  22: Required Laboratory Analytes  ................................ ................................ .................... 53 
Table  23: Pharmacokinetic and Antidrug Antibody Serum Blood Sample Timing  ................... 54 
56 
Table  25: Populations for Analysis  ................................ ................................ ............................. [ADDRESS_98007]  
HIV human immunodeficiency virus  
  

Incyte Corporation  Page 10 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Abbreviation s and 
Special Terms  Definition  
IB Investigator 's Brochure  
ICF informed consent form  
ICH International Council for Harmonis ation of Technical Requirements for  
Pharmaceuticals for Human Use  
  
  
ICR Independent Central Radiographic Review  
IEC independent ethics committee  
  
INR international normalized ratio  
  
irAE  immune -related adverse event 
IRB institutional review board  
  
IRT interactive response technology  
  
  
IV intravenous  
LDL  low-density lipoprotein  
MCC  Merkel cell carcinoma  
MedDRA  Medical Dictionary for Regulatory Activities  
MRI  magnetic resonance imaging  
mRNA  messenger RNA  
MTD  maximum tolerated dose  
NCCN  National Comprehensive Cancer Network  
NCI National Cancer Institute  
NE not evaluable  
ORR  overall response rate  
OS overall survival  
PD progressive disease  
PD-1 programmed cell death protein 1  
PD-L1 programmed cell death ligand protein 1  
PFS progression -free survival  
PK pharmacokinetic (s) 
PR partial r esponse according to RECIST1.[ADDRESS_98008]  v1.1 Response Evaluation Criteria in Solid Tumors  version 1.1  
  
RNA seq ribonucleic acid  sequencing  
SAE  serious adverse event  
SARS -CoV -2 severe acute respi[INVESTIGATOR_6507] 2 (a strain of the coronavirus 
family causing coronavirus disease 2019)  
SD stable disease  
TCR  T-cell receptor  
TEAE  treatment -emergent adverse event  
TIL tumor -infiltrating lymphocytes  
TSH  thyroid -stimulating hormone  
ULN  upper limit of normal  
UV ultraviolet  
WBC  white blood cell  

Incyte Corporation  Page 12 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  1. PROTOCOL  SUMMARY  
Protocol Title:   A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell 
Carcinoma  (POD1UM -201) 
Protocol Number:   INCMGA 0012 -201 
Objectives and Endpoints:  
Primary and secondary endpoints and objectives  are presented in Table  1. 
Table  1: Primary and Secondary Objectives and Endpoints  
Objectives  Endpoints  
Primary  
To determine the efficacy of INCMGA00012 in 
terms of the ORR in chemotherapy -naive 
participant s with advanced /metastatic MCC . ORR, defined as the percentage of participants 
having a n objective response ( CR or PR ), 
according to RECIST  v1.1, as determined by [CONTACT_89169].  
Secondary  
To determine the DOR, DCR, PFS , and OS in the 
chemotherapy -naive population with 
advanced/ metastatic MCC treated with 
INCMGA00012.  • DOR, defined as the time from an initial 
objective response (CR or PR) according to 
RECIST v1.1 until disease progression, or death 
due to any cause, as determined by [CONTACT_89169].  
• DCR, defined as the proportion of participants 
with either an objective response or SD lasting 
at least 6  months.  
• PFS, defined as the time from the start of 
therapy until disease progression, or death due 
to any cause, as determined by [CONTACT_89170].  
• OS, defined as the time from the start of the rapy 
until death due to any cause.  
To evaluate the safety of INCMGA00012 in 
participants  with advanced/ metastatic MCC.  Safety, determined by [CONTACT_77431], frequency, 
duration, and severity of AEs  using CTCAE v5.0 ; 
laboratory tests; vital signs; and ECGs.  
To determine the PK of INCMGA00012 
administered to participants with 
advanced/ metastatic MCC.  The PK of INCMGA00012 when given to 
participants with advanced /metastatic MCC, 
including C max, tmax, C min, and AUC t, will be 
summarized.  
Overall Design:  
Key study design elements  are presented in Table  2.  Further study details are presented after the 
table.  
Incyte Corporation  Page 13 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Table  2: Key Study Design Elements  
Study  Phase  Phase 2 
Clinical Indication  Advanced/ Metastatic MCC  
Population  Male and female participants at least [ADDRESS_98009] been diagnosed 
with advanced/ metastatic MCC .  Participants must be c hemo therapy -naive to 
be eligible.  
Participants who had received prior chemotherapy for MCC were enrolled up 
to Amendment 4.  
Number of 
Participants  Approximate ly 100 chemotherapy -naive  participant s will be enrolled .  The 
primary analysis is planned with approximately 60 chemother apy-naive 
participants, while the additional participants will be enrolled to  support 
confi rmation of efficacy and provide additional information on safety.    
Study Design  This is a  Phase 2, open -label, single -arm, multicenter  study . 
Estimated Duration 
of Study 
Participation  Participant s will participate in the study fo r up to approximately 3 years.  
The study consists of 3 periods:  screening, study drug treatment , and 
follow -up.  Participants have up to [ADDRESS_98010] to 
follow -up, or premature discontinuation for any other reason.  Participant s 
completing treatment or prematurely disco ntinuing the study w ill go to 
follow -up until study completion ( see Section  4.2). 
DSMB /DMC  Yes (external)  
Treatment Groups and Duration:  
This study will enroll participants with advanced/ metastatic MCC who are chemotherapy -naive .  
Participants with locally advanced disease are eligible only if they have had a recurrence 
following locoregional therapy  and are not considered amenable to furth er curative therapy with 
surgery or radiation.   The participants should not have received any prior therapy with 
PD-1/PD -L1 inhibitors .  Participant s will be required to provide a tumor biopsy (fresh or 
archival), at screening for central pathology review.   Participant s may be enrolled and initiate 
treatment before receiving results from the central pathology review.  All enrolled participant s 
will receive INCMGA00012 at the recommended Phase [ADDRESS_98011]  v1.1 ( Eisenhauer et al 2009 ). 
The study consists of 3 periods:  screening, study drug treatment , and follow -up. 
Treatment with study drug may continue up to  [ADDRESS_98012] to follow up, or premature discon tinuation 
for any other reason.  
Incyte Corporation  Page 14 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Eligible participant s will receive treatment with single -agent INCMGA [ZIP_CODE] 500 mg .  
Treatment will be administered by [CONTACT_12781] 60 minutes on Day 1 of each 28 -day cycle.  
Subsequent treatment cycles should be delayed until the following criteria are met: 
• Resolution of all immune -related toxicity to ≤ Grade 1 (with the exception of 
endocrinopathy that is controlled on hormonal replacement)  
• Resolution of all non –immune-related toxicity to ≤ Grade 1 or baseline (with the 
exception of alopecia or non –transfusion -dependent anemia) . 
Note: transient asymptomatic laboratory elevations ≤ Grade 3 do not require dose 
interruption if the participant is asymptomatic, and if the elevation is clinically 
insignificant and has been discussed with the medical monitor.  
Participants unable to re start study drug treatment ≤  12 weeks from the start of the treatment 
delay due to toxicity will be permanently di scontinued from study treatment.   Treatment delays 
of > 12 weeks for logistical reasons (eg, travel restrictions due to  COVID -19) may be acceptab le 
but must  be discussed with the medical monitor.   
The follow -up period will begin once a participant  has completed or prematurely discontinued 
the study treatment.  Participants will be evaluated for AEs and other safety parameters for up to 
[ADDRESS_98013] . 

Incyte Corporation  Page 15 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Table  3: Schedule of A ctivitie s 
Visit Day (Range)  Screening  Treatment  
EOT * Follow -Up Notes  
28 Days  Cycle 1  
Day 1  Cycle  ≥ 2 
Day 1  
(± 7 d) Q8W  
(± 7 d) Safety  
[ADDRESS_98014] Dose 
(± 7 d) * Survival  
Q12W  
(± 14 d)  * If EOT  visit is > [ADDRESS_98015] dose , the EOT 
visit will also serve as the 28 -day follow -up visit , and all 
EOT  and 28 -day follow -up required assessments will be 
performed.  
If EOT is ≤ [ADDRESS_98016] dose, the 28 -day 
follow -up visit is required.  
Administrative procedures  
Informed consent  X        
Interactive Response 
Technology  X X X  X    
Inclusion/exclusion criteria  X        
General and disease medical 
history  X        
Prior/concomitant medications  X X X  X X*  * Concomitant Medications are collected from signing of the 
ICF until [ADDRESS_98017] . 
Administer INCMGA [ZIP_CODE]   X X     Monitor participants for infusion reactions as per 
institutional guidelines.  
Safety a ssessments  
AE assessments  X* X X  X X*  * Adverse events are collected from signing of the ICF until 
[ADDRESS_98018]. 
Physical examination  X X X   X  A comprehensive examination is performed at screening and 
28-day safety follow -up.  All other scheduled examinations 
will be targeted . 
Vital signs  X X X   X   
12-lead ECG  X X X*   X  * Performed every third cycle (C4, C7, C10, etc) . 
ECOG performance status  X X X   X   
Efficacy a ssessments  
Tumor imaging/response 
assessments  X   X   X* Includes photography of skin disease (if target lesions) .  
Response assessments  are to be performed every [ADDRESS_98019] 12 months (including the Week 56 scan) and then 
every 12 weeks thereafter.  
* Scans during follow -up will only be performed for 
participant s continuing to be followed for disease status . 

Incyte Corporation  Page 16 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Table  3: Schedule of Activities  (Continued)  
Visit Day (Range)  Screening  Treatment  
EOT*  Follow -Up Notes  
28 Days  Cycle 1  
Day 1  Cycle ≥ 2  
Day 1  
(± 7 d) Q8W  
(± 7 d)  Safety  
[ADDRESS_98020] Dose  
(± 7 d)*  Survival  
Q12W 
(± 14 d)  * If EOT visit is > [ADDRESS_98021] dose, the EOT 
visit will also serve as the 28 -day follow -up visit, and all 
EOT and 28 -day follow -up required assessments will be 
performed.  
If EOT is ≤ [ADDRESS_98022] study anticancer therapy 
status      X X X  
Survival status        X Participants may be contact[CONTACT_89171].  
Clinical laboratory a ssessments  
Blood  chemistries  X X* X   X  * Not necessary on C1D1 if performed during screening 
within 7 days on C1D1 . 
Hematology  X X* X   X  * Not necessary on C1D1 if performed during screening 
within 7 days on C1D1 . 
Fasting lipid panel  X  X*     Participants are expected to fast prior to sample collect ion 
for all lipid panel analyses . 
* Performed every third cycle (C4, C7, C10, etc) . 
Coagulation panel  X  X*     * Performed every third cycle (C4, C7, C10, etc) . 
Endocrine panel  X  X      
Urinalysis  X  X*     * Performed every third cycle (C4, C7, C10, etc) . 
Pregnancy testing  X X* X   X  Serum pregnancy test is performed at screening and [ADDRESS_98023] dose.  For other cycles , either u rine- or 
serum -based testing is acceptable . 
* Not necessary on C1D1 if performed during screening 
within 7 days on C1D1.  

Incyte Corporation  Page 17 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Table  4: Pharmacokinetic  Sample Collections  
Sample  Collection  Purpose/  
Analysis  Screening  Treatment Period  
EOT*  Notes  
28 Days  Cycle 1 
Day 1 Cycle 2 
Day 1 
(± 7 d) Cycle 4 
Day 1  
(± 7 d) Cycle 6 
Day 1  
(± 7 d) Cycle 7 
Day 1  
(± 7 d) Cycle 8 
Day 1  
(± 7 d) Cycle 1 0 
Day 1  
(± 7 d) Cycle 12 
Day 1  
(± 7 d) * PK  samples are 
only collected at the EOT visit, 
including if the EOT visit also serves 
as the 28 -day safety follow -up visit  
Whole 
blood  PK serum  PK  X* X X X* X     Samples will be collected preinfusion 
on Day 1 of Cycles 1, 2, 4, 6, and 7.  
* Samples are collected 10 minutes 
postinfusion (± 10 minutes) and 4 hours 
postinfusion (± 15 minutes) on Day 1 
of Cycles 1 and 6.  

Incyte Corporation  Page 18 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Table  4: Pharmacokinetic  Sample Collections  (Continued)  
Sample  Collection  Purpose/  
Analysis  Screening  Treatment Period  
EOT*  Notes  
28 Days  Cycle 1 
Day 1 Cycle 2 
Day 1 
(± 7 d) Cycle 4 
Day 1  
(± 7 d) Cycle 6 
Day 1  
(± 7 d) Cycle 7 
Day 1  
(± 7 d) Cycle 8 
Day 1  
(± 7 d) Cycle 1 0 
Day 1  
(± 7 d) Cycle 12 
Day 1  
(± 7 d) * PK  samples are 
only collected at the EOT visit, 
including if the EOT visit also serves 
as the 28 -day safety follow -up visit  
 

Incyte Corporation  Page 19 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  2. INTRODUCTION  
2.1. Background  
The clinical study INCMGA 0012 -201 is a Phase 2, open -label, multicenter study designed to 
assess the clinical activity and safety of INCMGA00012 in participant s with advanced /metastatic 
MCC.  
Merkel cell carcinoma is a rare, aggress ive, cutaneous malignancy attributed to multiple factors , 
such as Merkel cell polyomavirus, UV irradiation, and immunosuppression.  This disease 
typi[INVESTIGATOR_89143] a poor prognosis with lower 
survival rates com pared with  other skin malignancies.  Surgery and/or radiation therapy are 
indicated and potentially curative for local -regional disease, and relapse is common 
(Bhatia  et al 2011 ). 
The 5 -year survival rates for patients with MCC are 75%, 59%, and 25% for primary localized 
tumors, tumors with regional lymph node metastases (or local recurrences), and tumors with 
distant metastases, respectively ( Becker 2010 ).  More than 30% of patients will develo p distant 
metastatic disease ( Voog et al 1999 ), and the 5-year survival rate for these patients is only 
approximately 10% (Allen et al 2005 ). 
Historically, metastatic MCC  has been treated with chem otherapy regimens similar to those used 
for small cell lung cancer ( NCCN 2017 ).  Platinum -based chemotherapy provides high initial 
response rates that are of short duration.  No survival advantage has ever been demonstrated for  
chemotherapy in this disease ( Cassler et al 2016 , Hughes et al 2014 , Lebbe et al 2015 , 
NCCN  2017 , Voog et al 1999 ).  Management of patients with recurrent , locally advanced , 
unresectable MCC is also challenging ( Becker et al 2017 ).  Similar to distant metastatic disease, 
patients with recurrent unresectable MCC require systemi c therapy to achieve disease control.  
Chemotherapy is also associated with risk of severe toxicity and toxic death, particularly among 
older patients.  Responses to second -line chemotherapy are anecdotal , and current guidelines 
recommend clinical studies  in this setting.  Other drug classes under early investigation for 
metastatic MCC include cytokines, adoptive T -cell therapy, toll -like receptor 4 agonists, and 
somatostatin analogues ( Schadendorf et al 2017 ). 
Immunotherapy is a promising new approach to treatment of advanced/ metastatic MCC .  
Updated results from  a study with the PD -L1 inhibitor, avelumab, showed an ORR  of 39.7% in 
chemo therapy -naive participant s (D'Angelo  et al 2 019) and 32% in participant s with 
chemo therapy -refractory metastatic disease, most of which were durable ( Kaufman et al 2016 ).  
Responses occurred in patients with both PD -L1+ and negative tumors and were independent of 
Merk el cell polyomavirus status.  Recently, updated results from a study of pembrolizumab, a 
PD-1 inhibitor, in participants with advanced MCC were published.  In this Phase 2 trial, the 
objective response rate was 56% in participants with distant metastatic or recurrent , locoregional 
MCC not amenable to definitive surgery or radiation therapy  (Nghiem et al 2019 ).  Based on 
these initial results, NCCN guidelines recommend pembrolizumab as a treatment option for 
patients with recurrent locally advanced disease ( NCCN 2019 ). 
Incyte Corporation  Page 20 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  2.2. Study Rationale  
Though initial results with checkpoint inhibitors are encouraging, there still rema ins an unmet 
medical need in the treatment of advanced/ metastatic MCC .  In particular, safety, efficacy, and 
convenience of therapy could be improved by [CONTACT_89172][INVESTIGATOR_014], either as 
monotherapy or as part of rational combination strategies.   Clinical trials also provide an 
important means by [CONTACT_89173][INVESTIGATOR_89144], when access is 
otherwise limited (eg, by [CONTACT_89174]).  
The study drug, INCMGA00012, is a humanized, IgG4 monoclonal antibody that recognizes 
human PD -1.  As of the data cutoff date of 23 SEP 2021, 660 unique patients had been exposed 
to INCMGA00012  as monotherapy at doses of 1 mg/kg  Q2W, 3 mg/kg Q2W, 3  mg/kg Q4W, 
10 mg/kg Q2W, [ADDRESS_98024] frequently reported 
TEAEs seen in pa tients who received INCMGA00012  monotherapy were asthenia (17.3%), 
fatigue (16.1%), and diarrhea (15.9%).  Immune -related TEAEs occurred in 27.4% of patients.  
The most frequent irAE was hypothyroidism (9.2%) and t he most frequent nonendocrine irAE 
was skin reactions (7.1%).  Most irAEs were Grade 1 or 2 in severity.   Grade  ≥ 3 irAEs occurred 
in 6.7% of participants with most frequent being acute kidney injury and pneumonitis 
(0.9% each).  
Furthe r details are presented in the  INCMGA00012  IB.  INCMGA00012  has shown clinical 
activity as monotherapy against a variety of solid tumors, including chemotherapy -naïve and 
previously treated Merkel cell carcinoma, lung, urothelial, renal, squamous carcinoma of the anal 
canal,  cervical, and endometrial carcinomas, as well as melanoma  (Berton et al 2021 , Grignani 
et al 2021 , Maio et al 2021 , Mehnert et al 2018 , Mehnert et al 2019 , Rao et al 2020 ). 
INCMGA00012 offers pot ential advantages over other checkpoint inhibitors in the treatment of 
MCC.  In particular, INCMGA00012 offers the convenience of Q4W flat dosing as opposed to 
the more frequent administration schedule s for avelumab  and pembrolizumab .  Development of 
combination therapi[INVESTIGATOR_89145] 's portfolio of immunomodulatory drugs using the 
INCMGA0001 [ADDRESS_98025] several advantages over weight -based doses, including convenience of 
preparation and administration, reducing errors in preparation calculation, and minimization of  
drug waste.  Body size –based doses and fixed doses of monoclonal antibodies have been 
evaluated, and the 2 approaches performed similarly, with body size –based doses not always 
offering an advantage in reducing variability of exposure ( Bai et al 2012 , Wang et al 2009 ). 
The proposed flat dose regimen of [ADDRESS_98026] -in-human monotherapy study ([STUDY_ID_REMOVED]) and benchmarking to 
pembrolizumab.   This dose -escalation study of INCMGA00012 evaluated 37 participants at the 
following doses:  1  mg/kg Q2W, 3 m g/kg Q2W, 3 mg/kg Q4W, 10 mg/kg Q2W, and 10 mg/kg 
Q4W.  While supra -dose proportionality was observed for AUC and C max for the first dose 
escalat ion from 1 mg/kg to 3  mg/kg, linear PK was shown from 3 mg/kg to 10 mg/kg.  No 
dose-limiting  toxicity was observed at any dose level, and an MTD was not reached.  
A population PK analysis was performed on these participants  to characterize the effect of body 
weight on the PK of INCMGA00012.  The plasma concentrations of INCMGA00012 can be 
Incyte Corporation  Page [ADDRESS_98027] -order elimination.  Higher clearance 
of INCMGA00012 was estimated for 1 mg/kg tha n the other dose groups.  Body weight 
dependence of clearance was characterized by a power relationship with an exponent of 0.911.  
A simulation was conducted to investigate the use of body weight based dosing and flat dosing 
for INCMGA00012  with the aim of  targeting a steady -state trough concentration of ~21 μg/mL, 
the median trough concentration for pembrolizumab ( Freshwater et al 2017 ).  The median 
INCMGA00012 exposure and distribution around the median at 500 mg Q4W wer e similar to 
7 mg/kg Q4W in the simulated population, which justified clinical exploration in an expansion 
cohort of the study.  The median steady -state concentration at 500 mg Q4W was 24.8 μg/mL, 
and 58% of participants had trough concentrations gre ater t han target concentration.  
Pharmacokinetic data were obtained from 15 participants who received INCMGA00012 500  mg 
Q4W in the Cohort Expansion Phase of Study INCMGA  0012 -101.  The observed AUC ∞ for 
500 mg Q4W is close to the steady state AUC t based on the p opulation PK analysis of 
weight -based dosing, as is the estimated clearance.  The estimated t ½ (333 h ) is slightly shorter 
than that from  the previous estimate of 409 h .  The mean trough plasma concentration on Cycle 2 
was 17.1 μg/mL , and the mean projecte d plasma C min,ss is 23.1 μg/mL (which meets or slightly 
exceeds the targeted concentration based on pembrolizumab data) with a mean accumulation 
index of 1.50.  Overall, the 500 mg Q4W dose had very similar PK properties to 3  mg/kg dosing, 
and has ~77% pro bability for steady state trough plasma concentration ≥  10 µg/mL, which is 
associated with maximum target engagement and greatest probability of efficacy.  Based on 
these observations, 500 mg Q4W was chosen as the dosing regimen for further development in 
the MCC  indication.  
2.3. Benefit/Risk Assessment  
Treatment directed at the PD -1/PD -L1 axis is a promising approach to MCC .  Phase 2 results 
with avelumab  and pembrolizumab  show efficacy in terms of durable tumor respo nse with 
preservation of health -related quality of life ( Kaufman et al 2018 , Nghiem et al 2019 ).  Safet y of 
these agents has been well -characterized, and no unexpected safety findings have been reported 
in this population with either  avelumab or pembrolizu mab.  Alternative treatments 
(eg, chemotherapy) are associated with both inferior activity and serious toxicities.  Based on 
these observations, the benefit /risk for INCMGA00012 should also be favorable, provided 
efficacy objectives  in the proposed study are met.  
Close oversight of study conduct will be provided through safety  team meetings and contact [CONTACT_89175] s.  Additionally, irAEs  will be monitored throughout the study as AEs 
of special interest with appropri ate guidance provided to investigators for their assessment and 
management.  
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of INCMGA00012 may be found in the IB. 
2.3.1.  Benefit/ Risk Assessment During the COVID -19 Pandemic  
An ESMO multidisciplinary panel highlighted the importance of clinical cancer research to find 
better therapeutic options for participants even during the pandemic, including potential 
investigational therapi[INVESTIGATOR_89146] a known survival benefit ( Curigliano 
Incyte Corporation  Page 22 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  et al 2020 ).  Data released based on real -world  experience  indicate that the use of 
immunotherapy does not appear to increase the risk of hospi[INVESTIGATOR_89147] -19 infection 
(Horn et al 2020 ) or cause an increased risk of mortality ( Lee et al 2020 , Sharafeldin et al 2021 ).  
Real world experience has also shown that the risk of SAEs is higher in cancer patients who 
were SARS -CoV -2 positive ; however , the incidence of SAEs is similar in patients treated with 
immunotherapy and chemotherapy.  Reported SAEs were generally COVID -19 related rather 
than related to the cancer therapy ( Mandala et al 2021 ). 
Vaccines to SARS -CoV -2 are recommended for patients with cancer by [CONTACT_89176], ASCO, and ESMO  (NCCN 2021a , ASCO 2021 , ESMO 2021 ).  There has been 
no indication of increased risk of new or worsening irAEs in patients receiving immunotherap y 
within a month of SARS -CoV -2 vaccination  (Malek  et al 2021 ). 
Participants will be monitored with safety procedures as described in Section  [ADDRESS_98028] of care.  Additional information regarding the 
flexibility of assessments/visits scheduling, where possible and warranted, and strategy for 
participant management during the dynamic pandemic as applicable is described in Appendix  D. 
3. OBJECTIVES AND ENDPO INTS  
The study objectives and end points  are presented in  Table  5. 
Table  5: Objectives and Endpoints  
Objectives  Endpoints  
Primary  
To determine the efficacy of INCMGA00012 in terms 
of the ORR in chemo therapy -naive participants with 
advanced /metastatic MCC.  ORR, defined as the percentage of participants having 
an objective response (CR or PR), according to 
RECIST  v1.1, as determined by [CONTACT_89169].  
Secondary  
To determine the DOR, DCR, PFS , and OS in the 
chemotherapy -naive population with 
advanced/ metastatic MCC treated with 
INCMGA00012.  • DOR, defined as the time from an initial objective 
response (CR or PR) according to RECIST v1.1 until 
disease progression, or death due to any cause, as 
determined by [CONTACT_89169].  
• DCR, defined as the proportion of participants with 
either an objective re sponse or SD lasting at least 
6 months.  
• PFS, defined as the time from the start of therapy 
until disease progression, or death due to any cause, 
as determined by t he ICR.  
• OS, defined as the time from the start of therapy 
until death due to any cause.  
To evaluate the safety of INCMGA00012 in 
participants  with advanced /metastatic MCC.  Safety, determined by [CONTACT_77431], frequency, duration, 
and severity of AEs  using CT CAE v5.0 ; laboratory 
tests; vital signs; and ECGs.  
To determine the PK of INCMGA00012 administered 
to participants with advanced /metastatic MCC.  The PK of INCMGA00012 when given to participants 
with advanced/ metastatic MCC, including C max, tmax, 
Cmin, and  AUC t, will be summarized.  
Incyte Corporation  Page 23 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Table  5: Objectives and Endpoints  (Continued)  
Objectives  Endpoints  
Exploratory  
To determine the efficacy of INCMGA00012 in terms 
of the ORR, DOR, DCR, PFS, and OS in the full study 
population (chemotherapy -naive and chemotherapy -
refractory) with advanced/metastatic MCC.  
 
Note:  Chemotherapy -refractory participants enrolled 
before  implementation of Amendment 5 will be 
included in these analyses.  • ORR, defined as the percentage of participants 
having an objective response (CR or PR), according 
to RECIST  v1.1, as determined by [CONTACT_89169].  
• DOR, defined as the time from an initial objective 
response (CR or PR) according to RECIST v1.1 until 
disease progression, or death due to any cause, as 
determined by [CONTACT_89169].  
• DCR, defined as  the proportion of participants with 
either an objective response or SD lasting at least 
6 months.  
• PFS, defined as the time from the start of therapy 
until disease progression, or death due to any cause, 
as determined by [CONTACT_89170].  
• OS, defined as the time fr om the start of therapy 
until death due to any cause.  

Incyte Corporation  Page 24 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  4. STUDY DESIGN  
4.1. Overall Design  
The clinical study INCMGA 0012 -201 is a Phase 2, open -label, single -arm, multicenter study 
designed to assess the clinical activity and safety of INCMGA00012 in participant s with 
advanced /metastatic MCC .  This study will  enroll participant s with advanced /metastatic MCC  
who are chemo therapy -naive.  Participants with locally advanced disease are eligible only if they 
have had a recurrence following locoregional therapy and are  not considered amenable to further 
curative therapy with surgery or radiation.  The participants should not have received any prior 
therapy with PD -1/PD -L1 inhibitors .  All participants  must submit tissue samples (fresh or 
archival) for central pathology review .  Participants who do not have MCC confirmed by 
[CONTACT_89177] ( see 
Section  5.5). 
All participant s who meet the eligibility criteria during screening will  receive treatment with 
INCMGA00012.  The primary endpoint is ORR in chemo therapy -naive participants  as 
determined by [CONTACT_89178]  v1.1.  
Approximately [ADDRESS_98029] 6 months after confirmed response.  If the study 
meets the  predefined efficacy threshold at the primary analysis  (see Section  10.1), the final 
analysis will occur after all [ADDRESS_98030] to follow -up, or premature discontinuation for any oth er reason  listed 
in Section  7.1. 
The study consists of 3 periods:  screening, study drug treatment , and follow -up. 
Eligible participant s will receive  treatment with single -agent INCMGA [ZIP_CODE] 500 mg 
administered by [CONTACT_12781] 60 minutes on Day 1 of each 28 -day cycle.  Subsequent 
treatment cycles should be delayed until  the following criteria are met:  
• Resolution of all immune -related toxicity to ≤ Grade 1 (with the exception of  
endocrinopathy that is controlled on hormonal replacement)  
• Resolution of all non –immune -related toxicity to ≤ Grade 1 or baseline (with the 
exception of alopecia or non –transfusion -dependent anemia)  
Note:   Transient asymptomat ic laboratory elevations ≤ Grade 3 do not require 
dose interruption if the participant is asymptomatic, and if  the elevation is 
clinically insignificant and has been discussed with the medical monitor.  
Incyte Corporation  Page 25 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Participants unable to restart study drug treatment ≤  12 weeks from the start of the treatment 
delay due to toxicity will be permanently discontinued from study treatment  (see 
Section  [IP_ADDRESS] ).  Treatment delays of > 12 weeks for logistical reasons (eg, travel restrictions 
due to COVID -19) may be acceptable but must be discussed with the medical monitor.  
The follow -up period will begin once a participant  has completed treatment or prematurely 
discontinued the study treatment.  Participants will be evaluated for AEs and other safety 
parameters for up to [ADDRESS_98031] . 
Once a participant  discontinues treatment they enter the  follow -up period and will be assessed 
for survival until study completion.  Participant s who discontinue study treatment without 
experiencing disease progression will enter the follow -up period and continue to undergo tumor 
assessments according to the schedule of activities (see Table  3) until they experience disease 
progression, the start of a new anticancer treatment, withdrawal of consent, lost to follow -up, the 
end of the study, or death.  
The complete study -specific  assessment  schedule required for participant s in this clinical study is 
presented in Table  3.  The analytes to be evaluated in the safety laboratory analyse s are found in 
Table  22.  Details regarding the sample collection for PK  analyses are defined 
in Table  4. 
4.2. Overall Study Duration  
The study begins when the first participant signs the ICF.  Participants may receive study 
treatment for up to [ADDRESS_98032] .  The i nvestigator is to notify the IRB /IEC in writing of the 
study 's completion or early termination, send a copy of the notification to the sponsor or 
sponsor 's designee, and retain [ADDRESS_98033] of the study.  The establishment, composition, roles, duties, and 
responsibilities of the DMC will be addre ssed in the DMC charter.  

Incyte Corporation  Page 26 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Preplanned analyses of safety will be provided to an independent DMC as specified in the DMC 
charter.   In addition, the DMC will make recommendations to the sponsor at a planned interim 
analysis  (see Section  10.5).  In terms of efficacy, the DMC will use the guidelines provided for 
recommendation of either continuation or early termination of the study at the interim analysis.  
Additionally, the DMC will review safety data of the ongoing study at regular intervals as  
specified in the DMC Charter.   The process by [CONTACT_89179].  
As of Protocol  Amendment 6, the DMC has reviewed the data for the interim analysis.  The 
preliminary efficacy based on the ORR assessed by [CONTACT_89180] , and the 
DMC recommended the study to proceed as planned.  
Incyte Corporation  Page 27 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  5. STUDY POPULATION  
Deviations from eligibility criteria are not allowed because they can potentially jeopardize the 
scientific integrity of the study, regulatory acceptability, and/or participant  safety .  Therefore, 
adherence to the criteria as specified in the Protocol is essential .  Prospective approval of 
Protocol deviations to recruitment and enrollment criteria, also known as Protocol wai vers or 
exemptions, are not permitted.  
5.1. Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following criteria apply:  
1. Signed informed consent . 
2. Men and women, aged 18 or older (or as applicable per local country requir ements).  
3. Diagnosis of MCC  with distant metastatic disease or recurrent , advanced locoregional  
disease  not amenable to surgery or radiation . 
4. ECOG performance status  of 0 to 1 (see Table  21). 
5. Measurable  disease according to RECIST  v1.1.   Tumor lesions that are located in a 
previously irradiated area or in an area subjected to other locoregional therapy should 
only be selected as  target lesions if progression has been demonstrated in such lesions . 
6. Availability of tumor tissue (fresh or archival) for central pathology review.  
7. Willingness to avoid pregnancy or fathering children based on the criteria below.  
a. Men must agree to take ap propriate precautions to avoid fathering children (with at 
least 99% certainty) from screening through [ADDRESS_98034] 99% effecti ve in preventing pregnancy ( see Appendix  A) 
should be communicated to the participant s and their understanding confirmed.   
b. Wom en of childbearing potential must have a negative serum pregnancy test at 
screening and before the first dose on Day [ADDRESS_98035]  agree to take appropriate 
precautions to avoid pregnancy (with at least 99% certainty) from screening through 
[ADDRESS_98036] 
99% effective in preventing pregnancy ( see Appendix  A) should be communicated to 
the participant s and their understanding confirmed.  
c. Women of nonchildbearing potential (ie, surgically sterile with a hysterectomy and/or 
bilateral oophorectomy OR ≥  [ADDRESS_98037] 50 years of age) 
are eligible.  
5.2. Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply:  
1. Prior systemic therapy for MCC , including  chemotherapy and  prior P D-1– or  
PD-L1–directed therapy.  
2. Treatment with anticancer drugs or participation in another interventional clinical study  
within [ADDRESS_98038] administration of study drug.  
Incyte Corporation  Page 28 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  3. Participant h as not recovered to ≤ Grade 1 or baseline from toxic effects of prior therapy 
(with the exc eptions for anemia not requiring transfusion support and any grade of 
alopecia) and/or complications from prior surgical intervention within [ADDRESS_98039] dose of study treatment  or 
radiation therapy to the thoracic region  that is > [ADDRESS_98040] dose 
of study  treatment . 
5. Known CNS metastases and/or carcinomatous meningitis.  
Note:   Participant s with previously treated brain metastases may participate provided that 
they are stable (without evidence of progression by [CONTACT_89181] [ADDRESS_98041] returned to baseline), 
have no ev idence of new or enlarging brain metastases or CNS edema, and have not 
required steroids for at least [ADDRESS_98042] dose of study drug.  
6. Any k nown additional malignancy that is progressing or requires active treatment, or 
history of other maligna ncy within 3 years of study entry with the exception of cured 
basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate 
intraepi[INVESTIGATOR_11901], carcinoma in situ of the cervix, or other noninvasive or indolent 
malignancy, or  cancers from which the participant has been disease -free for > 1 year, 
after treatment with curative intent . 
7. Participants with laboratory values at screening defined in Table  6. 
Table  6: Exclusionary Laboratory Values  
Laboratory Parameter  Exclusion Criterion  
Hematology  
A Platelets  < 100 × 109/L 
B Hemoglobin  < 9 g/dL  
C ANC  < 1.5 × 109/L 
Hepatic  
D ALT  > 2.5 × ULN  OR > 5 × ULN for participants with liver metastases  
E AST  > 2.5 × ULN  OR > 5 × ULN for participants with liver metastases  
F Bilirubin/total bilirubin  ≥ 1.5 × ULN unless conjugated bilirubin is ≤ ULN (conjugated bilirubin 
only needs to be tested if total bilirubin exceeds the ULN).  If there is no 
institutional ULN, then direct bilirubin must be < 40% of total bilirubin.  
Renal  
G Calculated creatinine clearance  < 30 mL/min  
Coagulation  
H INR or PT  > 1.5 × ULN  
I aPTT  > 1.5 × ULN  
Incyte Corporation  Page 29 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  8. Evidence of interstitial lung disease or active, noninfectious pneumonitis.  
9. Participants  with impaired cardiac function or clinically significant cardiac disease:  
a. [LOCATION_001] Heart Association Class III or IV cardiac disease, including preexisting 
clinically significant ventricular arrhythmia, congestive heart failure, or 
cardiomyopathy . 
b. Unstable angina pectoris ≤ 6 months before  study participation . 
c. Acute myocardial infarction ≤ 6 months before  study participation . 
d. Other clinically significant heart disease (ie, uncontrolled ≥ Grade 3 hypertension, 
history of labile hypertension, or poor compliance with an anti hypertensive regimen).  
Must have recovered (to baseline or ≤  Grade 1) from toxicity associated with prior  
treatment.  
10. Active autoimmune disease requiring systemic immunosuppression in excess of 
physiologic maintenance doses of corticosteroids.  
11. Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or 
antiviral treatment.  
12. Known active hepatitis A, B, or C or active infection s requiring systemic antibiotics . 
13. Has received a live vaccine within 28 days of planned start of study therapy.  
Note:   Examples of live vaccines include, but are not limited to, the following:  measles, 
mumps, rubella, chicken pox/zoster, yellow fever, r abies, Bacillus Calmette –Guérin , and 
typhoid vaccine.  Seasonal influenza vaccines for injection are generally killed virus 
vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are 
live-attenuated vaccines and are not allowed.  
14. Current use of prohibited medication as described in Section  6.6.[ADDRESS_98043] measures (eg, antihistamines and corticosteroids).  
16. Participant lacks the ability or is unlikely, in the opi[INVESTIGATOR_871], to comply 
with the Protocol requirements . 
17. Participant who is pregnant  or breastfeeding  
18. Any condition that wou ld, in the investigator 's judgment, interfere with full participation 
in the study, including administration of study drug /treatment  and attending required 
study visits; pose a significant risk to the participant; or interfere with interpretation of 
study data.  
19. History of organ transplant , including allogeneic stem cell transplantation.  
20. Known allergy or hypersensitivity  to any component of the study drug formulation.  
21. Participants  who are known to be HIV -positive , unless all of the following criteria are 
met: 
a. CD4+ count ≥ [ADDRESS_98044] a MCC diagnosis by 
[CONTACT_51723], but initiated study treatment will be removed from study unless , in the 
judgment of the investigator , the participant  is benefiting from treatment  and there is no evidence 
of disease progression or unacceptable toxicity.  The sponsor’s medical monitor and the 
investigator will jointly evaluate such cases and make a decision regarding continued therapy on 
a case -by-case basis .  However , these participant s may not be included in the efficacy analysi s 
population (see Section  10.2) and may be  replace d by [CONTACT_89182].  
Incyte Corporation  Page 31 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  6. STUDY TREATMENT  
6.1. Study Treatment Administered  
The study treatment information  is presented in Table  7. 
Table  7: Study Treatment Information  
Study treatment name:  [CONTACT_89234] [ZIP_CODE]  
Dosage formulation:  Liquid formulation supplied as 250  mg vials 
Unit dose strength/dosage level:  500 mg Q4W  
Route of  administration:  IV 
Administration instructions:  Administered IV over 60  minutes  (+ 15 minutes)  through a filter .  
Participants should be monitored for infusion reactions during the 
infusion as per institutional guidelines.  
Packaging and labeling:  INCMGA00012 will be provided in a 250  mg vial. 
Each vial will be labeled as required per country requirement.  
Storage:  Upright under refrig eration at 2°C -8°C (36°F -46°F) p rotected 
from light . 
6.2. Preparation , Handling , and Accountability  
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study treatment s received and any discrepancies are reported and 
resolved before use of the study treatmen t. 
Only participants enrolled in the study may receive study treatment , and only authorized site 
staff may supply or administer study treatmen t.  All study treatment  must be stored in a secure, 
environmentally controlled, and monitored (manual or automated) area in accordance with the 
labeled storage conditions with access limited to the investigator and authorized site staff.  
The investigator  (or designee)  is responsible  for study treatment  accountability, reconciliation, 
and record maintenance (ie, receipt, reconciliation, and final disposition records) .  Inventory and 
accountability records must be maintained and readily available for inspection by [CONTACT_89183] .  The 
investigator or designee must maintain records that document:  
• Delivery of study drug to the study site.  
• Inventory of study drug at the site.  
• Participant use of the study dru g including vial counts from each supply dispensed.  
• Lot numbers and/or vial numbers of  study drug used to prepare the infusion solution.  
Incyte Corporation  Page [ADDRESS_98045] and retain all used, unused, and partially used containers of study drug 
until verified by [CONTACT_11200] (unless otherw ise agreed to by [CONTACT_456]) .  At the 
conclusion of the study, the investigator or designee will oversee shipment of any remaining 
study drug back to the sponsor or its designee for destruction according to institutional standard 
operating procedures .  If local procedures mandate on -site destruction of investigational supply, 
the site should (where local procedures allow) maintain the investigational supply until the study 
monitor inspects the accountability records in order to evaluate compliance and accu racy of 
accountability by [CONTACT_3878] .  At sites where the study drug is destroyed before 
monitor inspection, the monitors rely on documentation of destruction per the site Standard 
Operating Procedures . 
Further guidance and information for the final disposition of unused study treatment s are 
provided in the Pharmacy Manual . 
6.3. Measures to Minimize Bias:  Randomization and Blinding  
Not applicable . 
6.4. Study Treatment Compliance  
Compliance with all study -related treatments should be emphasized to the participant by [CONTACT_89184], and appropriate steps should be taken to optimize compliance during the study . 
Compliance with study drug administration  will be calculated by [CONTACT_89185]/designee.  
6.5. Dose Modifica tions 
Dose interruptions of INCMGA [ADDRESS_98046] meet the treatment continuation 
criteria noted in (see Section  4.1) before  administration of INCMGA00012.  If the criteria are not 
met at the beginning of a treatment cycle, INCMGA00012 infusion may be delayed up to 
[ADDRESS_98047] be discontinued due to unacce ptable toxicity, then the participant should 
be withdrawn from active treatment and enter the follow -up period of the study.  
Incyte Corporation  Page 33 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  6.5.1.  Management of Suspected Infusion Reactions  
Infusion or hypersensitivity reactions may be observed with administration of any foreig n 
protein.  Premedication with acetaminophen /paracetamol  and a histamine  blocker should be 
considered for participants who have had previous systemic reactions to protein product 
infusions or when recommended by [CONTACT_10569].  
Guidelines for managem ent of suspected infusion reactions are provided in Table  8.  Grade 3 or 
Grade 4 infusion reactions should be reported within 24 hours to the study med ical monitor 
regardless of whet her criteria for reporting as a  SAE are met.  
Table  8: Guidelines for Management of Suspected Infusion Reactions  
Grade  Descriptiona Treatment  Subsequent Infusions  
1 Mild reaction; interrupt or slow the 
rate of infusion; intervention not 
indicated.  Monitor vital signs closely 
until medically stable.  Premedication with a n 
antipyretic (eg, 
acetaminophen/paracetamol ) 
and a histamine blocker  
(eg, diphenhydramine)  should 
be considered , or as per 
institutional guidelines . 
2 Requires infusion interruption but 
responds promptly to symptomatic 
treatment (eg, antihistamines, 
analgesic/antipyretic , narcotics, 
IV fluids); prophylactic medications 
indicated for ≤  [ADDRESS_98048] occurrence:   Stop 
infusion and initiate 
appropriate medical measures 
(eg, IV fluids, antihistamines , 
analgesic/antipyretic, narcotics, 
per institutional preferences).  
Monitor vital signs until 
medically stable.  
If symptoms resolve within 
1 hour, infusion may be 
resumed at 50% of the original 
infusion rate.  
Subsequent occurrences 
(despi[INVESTIGATOR_89148]):   Permanently 
discontinue treatment.  Premedicate at least 
30 minutes before infusion 
with antihistamines 
(eg, diphenhydramine 50  mg 
PO or comparable  dose of 
antihistamine ) and 
acetaminophen / paracetamol  
(500-1000  mg PO  or 
equivalent dose of 
analgesic/antipyretic ). 
Additional supportive 
measures may be acceptable 
(per institutional preference) 
but should be discussed w ith 
medical monitor.   
Next infusion should start at 
50% of the original infusion 
rate.  If no reaction, the rate 
of infusion can be increased 
by 25% every 15 minutes 
until a rate of 100% has been 
reached.  Subsequent 
infusions can begin at 100%.  
Incyte Corporation  Page 34 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Table  8: Guidelines for Management of Suspected Infusion Reactions  (Continued)  
Grade  Descriptiona Treatment  Subsequent Infusions  
3 or 4  Grade 3:   Prolonged (ie, not rapi[INVESTIGATOR_38194]/or brief interruption 
of infusion); recurrence of 
symptoms following initial 
improvement  or rechallenge ; 
hospi[INVESTIGATOR_38195] (eg, renal 
impairment, pulmonary infiltrates).  
Grade 4:   Life-threaten ing; pressor 
or ventilatory support indicated.  Stop infusion and initiate 
appropriate medical therapy 
(eg, IV fluids, antihistamines 
analgesic/antipyretic , narcotics, 
oxygen, pressors, epi[INVESTIGATOR_238], 
corticosteroids, per institutional 
preferences).  
Monitor v ital signs frequently 
until medically stable.  
Hospi[INVESTIGATOR_55516].  Discontinue study treatment.  
Note:   NCI CTCAE Grade  3 
infusion related reaction  
(NCI CTCAE v5):  if rapi[INVESTIGATOR_38194]/or to brief 
interruption of infusion, 
study treatment  does not 
need to be permanently 
discontinued.  
a Per NCI CTCAE v 5.0, appropriate resuscitation equipment should be available at the bedside and a physician readily available 
during the period of study drug administration.  
6.5.2.  Procedures for Participants Exhibiting Immune -Related Adverse Events  
Adverse events of a potential immunologic etio logy or irAEs may be defined as an AE of 
unknown etiology, associated with drug exposure and consistent with an immune phenomenon.  
Immune -related AEs may be predicted based on the nature of the compounds, their mechanism 
of action, and reported experience  with immunotherapi[INVESTIGATOR_89149] a similar mechanism of 
action.  Special attention should be paid to AEs that may be suggestive of potential irAEs.  An 
irAE can occur shortly after the first dose or several months after the last dose of treatment.  
If an irA E is suspected, efforts should be made to rule out neoplastic, infectious, metabolic, toxin 
or other etiologic causes be fore labeling an AE as an irAE.  
Recommendations for management of specific irAEs known to be associated with 
INCMGA00012  and other PD -1 inhibitors (eg, pembrolizumab, nivolumab) are detailed in the 
sections below.  
Algorithms for evaluation of selected immune toxicities that have previously been attributed to 
PD-1 inhibitors and m anagement guidance for irAEs not detailed elsewhere in the Pr otocol 
should follow the American Society of Clinical Oncology or European Society for Medical 
Oncology Clinical Practice Guideline s or NCCN Guidelines  (Brahmer et al 2018 , Haanen  et al 
2017 , NCCN 2021 b. 
[IP_ADDRESS].  Immune -Mediated Pneumonitis  
Participants with symptomatic pneumonitis should immediately stop receiving study treatment 
and have an evaluation.  The evaluation may include bronchoscopy and pulmonary function tests 
to rule out other causes such as infection.  Recommendations for manag ement of  study 
drug-associated pneumonitis are detailed in Table  9. 
Incyte Corporation  Page 35 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Table  9: Recommended Approach to Handling Pneumonitis  
Study Drug –Associated 
Pneumonitis  Withhold/Discontinue  
Study Treatment  Supportive Care  
Grade 1 (asymptomatic)  No action.  Intervention not indicated.  
Grade 2  Withhold study treatment.  May return to 
treatment if condition improves to ≤ Grade  1. 
Permanently discontinue if toxicity does not 
resolve within [ADDRESS_98049] dose or 
inability to reduce corticosteroid to ≤  10 mg 
per day prednisone or equivalent within 
12 weeks.  • Evaluate participants with 
suspected pneumonitis with 
radiograph ic imaging and initiate 
corticosteroid treatment.  
• Administer systemic 
corticosteroids per local practice 
followed by [CONTACT_13217].  
• Add prophylactic antibiotics for 
opportunistic infections.  Grades 3 and 4 or 
recurrent Grade 2  Permanently discontinue study treatment.  
[IP_ADDRESS].  Immune -Mediated Colitis /Enterocolitis /Diarrhea  
Participants should be carefully monitored for signs and symptoms of colitis (eg, diarrhea, 
abdominal pain, mucus, or blood in stool, with or without fever).  In symptomatic participants, 
infectious etiologies should be ruled out, and endoscopic evaluation  should be considered for 
persistent or severe symptoms.  Recommendations for management of enterocolitis are shown in 
Table  10. 
Table  10: Recommended Approach for Handling Colitis/ Enterocolitis/Diarrhea  
Study Drug –Associated 
Colitis/ Enterocolitis/  
Diarrhea  Withhold/Discontinue  
Study Treatment  Supportive Care  
Grade 1  No action.  None.  
Grade 2  or 3 Withhold study 
treatment  until 
≤ Grade  1. • Consider prompt initiation of standard anti -diarrheal 
agents  or and other necessary supportive care as 
needed (eg, oral and/or IV fluids) . 
• Administer systemic corticosteroids per local practice 
followed by [CONTACT_13217].  
• Consider prophyl actic antibiotics per local practice.  
• Consider gastrointestinal consultation and performing 
endoscopy to rule out colitis.  
• Consider stool sample evaluation to rule out 
Clostridium difficile (C. diff) and infectious etiologies.  Grade 4 or recurrent 
Grade  3 Permanently 
discontinue study 
treatment.  
[IP_ADDRESS].  Immune -Mediated Hepatitis  
Liver chemistry testing (hepatic transaminase and bilirubin levels) should be monitored and 
participants assessed for signs and symptoms of hepatotoxicity before each dose of 
INCMGA00012.  In participants with hepatotoxicity, infectious or malignant causes  should be 
ruled out, and frequency of liver chemistry monitoring increased until resolution.  
Recommendations for management of hepatitis are shown in Table  11. 
Incyte Corporation  Page 36 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Table  11: Recommended Approach for Handling Hepatitis  
Study Drug –Associated Hepatitis  Withhold/Discontinue  
Study Treatment  Supportive Care  
Grade 1  No action.  Increase frequency of liver chemistry 
monitoring  to twice per week until liver 
chemistry tests return to baselinea. 
Grade 2  Withhold study treatment.  Systemic corticosteroids are indicated 
(initial dose of 0.5 -1 mg/kg per day of 
prednisone or equivalent).  Taper as 
appropriate.  
Grades [ADDRESS_98050] 
increases ≥ 50% and lasts ≥  1 week  Permanently discontinue 
study treatment.  Treatment with systemic corticostero ids 
should be initiated (initial dose of 
1-2 mg/kg per day of prednisone or 
equivalent).  Taper as appropriate.  
a In addition to ALT and AST, consider monitoring total bilirubin, direct bilirubin, and alkaline phosphatase at an increased 
frequency . 
[IP_ADDRESS].  Immune -Mediated Endocrinopathies  
[IP_ADDRESS].1.  Hypophysitis  
Monitor for signs and symptoms of hypophysitis (including hypopi[INVESTIGATOR_297] ).  Recommendations 
for management of hypophysitis are shown in Table  12. 
Incyte Corporation  Page 37 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Table  12: Recommended Approach for Handling Hypophysitis  
Study Drug –Associated 
Hypophysitis  Withhold/Discontinue  
Study Treatment  Supportive Care  
Grade 1  No action.  None.  
Grades 2 (asymptomatic)  Withhold until ≤ Grade  1. 
May restart INCMGA00012 treatment 
after controlled by [CONTACT_89186].  Administer hormonal replacement as 
clinically indicated.  
Grade 2 (symptomatic, 
e.g. headaches, visual 
disturbances)  Withhold until ≤ Grade 1 . 
May restart INCMGA00012 after 
controlled with hormone replacement, if 
indicated, and steroid  taper is complete.  Administer corticosteroids at initial dose 
of 1 to 2 mg/kg/day prednisone or 
equivalent followed by a taper and 
initiate other hormonal replacements as 
clinically indicated. Consult with 
endocrinologist as needed.  
Grades 3 or 4 
(sympto matic)  Permanent discontinuation should occur 
if after withholding INCMGA00012 the 
toxicity does not resolve to ≤ Grade [ADDRESS_98051] dose of 
INCMGA00012 treatment, or if 
corticosteroid dosing cannot be reduced 
to ≤ [ADDRESS_98052] 
earlier at the investigator’s discretion, if 
corticosteroids and/or hormone 
replacement therapy cannot balance the 
participant's pi[INVESTIGATOR_301].  Administer corticosteroids at initial dose 
of 1 to 2 mg/kg/day prednisone or 
equivalent followed by a taper and 
initiate other hormonal replacements as 
clinically indicated.  
Consult with endocrinologist as needed.  
[IP_ADDRESS].2.  Thyroid Disorders  
Monitor participants for changes in thyroid function (at the start of treatment, periodically during 
treatment, and as indicated based on clinical evaluation) and for clinical signs and symptoms of 
thyroid disorders.  Recommendations for management of thyr oid disorders are shown in 
Table  13. 
Table  13: Recommended Approach for Handling Thyroid Disorders  
Study Drug –Associated 
Thyroid Disorders  Withhold/Discontinue  
Study Treatment  Supportive Care  
Hypothyroidism  
Grades 1 and 2  No action.  None.  
Grades 3 and 4  Withhold until ≤ Grade 1 or is otherwise 
clinically stable.  Initiate thyroid replacement hormones 
(eg, levothyroxine or liothyronine) per 
standard of care.  
Hyperthyroidism  
Grades 1 and 2  No action.  None.  
Grades 3 and 4  Withhold until ≤ Grade 1 or is otherwise 
clinically stabl e. Initiate symptomatic management.  
Incyte Corporation  Page 38 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  [IP_ADDRESS].3.  New Onset Type 1 Diabetes Mellitus /Hyperglycemia  
Monitor participants for hyperglycemia or other signs and symptoms of diabetes mellitus.  
Recommendations for management of diabetes mellitus are shown in Table  14. 
Table  14: Recommended Approach for Handling New Onset Type 1 Diabetes 
Mellitus /Hyperglycemia  
Study Drug –Associated 
Diabetes Mellitus  Withhold/Discontinue  
Study Treatment  Supportive Care  
Grades 1 and 2  No action.  Intervention not indicated.  
Grade s 3 and 4  
Type  1 diabetes mellitus 
(or hyperglycemia)  Withhold study drug  until ≤ Grade 1 
or is otherwise clinically stable . Initiate treatment with antihyperglycemics or 
insulin as clinically indicated.  
[IP_ADDRESS].4.  Adrenal Insufficiency  
Monitor for signs and symptoms of adrenal insufficiency .  Recommendations for management of 
adrenal insufficiency  are shown in  Table  15. 
Table  15: Recommended Approach for Handling Adrenal Insufficiency  
Study Drug -Associated 
Adrenal Insufficiency  Withhold/Discontinue  
Study Treatment  Supportive Care  
Grade 1  No action.  Intervention not indicated.  
Grade 2  Withhold study drug until ≤ Grade 1 or 
is otherwise clinically stable.  Initiate treatment with hormone 
replacement as clinically indicated.  
Grades 3 and 4  Withhold until ≤ Grade 1 after 
corticosteroid taper to ≤  10 mg/day 
prednisone or  equivalent or is otherwise 
clinically stable.  Initial dose of 1 to 2 mg/kg/day 
prednisone or equivalent followed by a 
taper and hormone replacement as 
clinically indicated.  
[IP_ADDRESS].  Immune -Mediated Nephritis and Renal Dysfunction  
Monitor participants for changes in renal function.  Recommendations for management of 
nephritis and renal dysfunction are shown in Table  16. 
Table  16: Recommended Approach for Handling Nephritis and Renal Dysfunction  
Study Drug –Associated 
Nephritis and Renal Dysfunction  Withhold/Discontinue  
Study Treatment  Supportive Care  
Grade 1  No action.  Intervention not indicated.  
Grade 2  or Grade 3 increased 
blood creatinine  Withhold study treatment  until 
≤ Grade 1 . Administer  corticosteroids per local 
practice followed by [CONTACT_13217].  
Grade 4 increased blood creatinine  Permanently discontinue study 
treatment.  
[IP_ADDRESS].  Immune -Mediated Skin Reactions  
Immune -mediated rashes, including Stevens -Johnson syndrome, toxic epi[INVESTIGATOR_194] 
(some cases with fatal outcome), exfoliative dermatitis, and bullous pemphigoid, can occur.  
Monitor participants for suspected severe ski n reactions and exclude other causes.  
Recommendations for management of skin reactions are shown in Table  17. 
Incyte Corporation  Page 39 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Table  17: Recommended Approach for Handling Skin Reactions  
Study Drug –Associated Skin 
Reactions  Withhold/Discontinue  
Study Treatment  Supportive Care  
Grade 1  No action.  Intervention not indicated.  
Grade 2  No action.  Manage with topi[INVESTIGATOR_89150].  
Grade 3a or persistent Grade 2 
(≥ 2 weeks)  
OR 
Suspected Stevens -Johnson 
syndromeb Withhold study treatment  until ≤ 
Grade 1 after corti costeroid taper 
to ≤10mg/day prednisone or 
equivalent . • Administer corticosteroids per local 
practice followed by [CONTACT_13217]. 
Additionally, oral antihistamines such 
as diphenhydramine or famotidine (per 
institutional preference) may be utilized 
as needed. Refer to dermatology if no 
resolution with these measures.  
• Refer to dermatology if SJS or TEN is 
suspected . 
Grade  4 
OR 
Confirmed Stevens -Johnson 
syndrome or toxic epi[INVESTIGATOR_89151].  • Initial dose of 1 to 2 mg/kg/day 
prednisone or equivalent followed by a 
taper.  
• Refer to dermatology consult.  
a Participants with Grade 3 rash in the absence of desquamation, with no m ucosal involvement, not requiring systemic steroids, 
and resolving or improving to ≤ Grade [ADDRESS_98053] to interrupt INCMGA00012.  Permanent discontinuation 
of study treatment may be necessary if there is recurrence of Grade 3 after resumin g the study treatment.  
b Grade 3 Stevens -Johnson syndrome is defined as skin sloughing covering < 10% BSA with associated signs (eg, erythema, 
purpura, epi[INVESTIGATOR_89152], mucous membrane detachment).  Grade 4 Stevens -Johnson syndrome is defined as skin 
sloughing covering 10 -30% BSA with associated signs (eg, erythema, purpura, epi[INVESTIGATOR_89152], mucous membrane 
detachment).  
c Toxic epi[INVESTIGATOR_89153] 4 by [CONTACT_89187] ≥ 30% BSA with associated 
symptoms (eg, erythema, purpura, epi[INVESTIGATOR_89152])  
[IP_ADDRESS].  Immune -Mediated Myocarditis  
Immune -mediated myocarditis can occur (some cases with fatal outcome).  Monitor participants 
for suspected myocarditis and exclude other causes .  Recommendations for the management of 
immune -mediated myocarditis are shown in Table  18. 
Table  18: Recommended  Approach for Handling Myocarditis  
Study Drug –Associated 
Myocarditis  Withhold/Discontinue  
Study Treatment  Supportive Care  
Grade 2 , 3, and 4  Permanently discontinue study 
treatment.  • Treatment with systemic corticosteroids 
should be initiated (initial dose of 
1-2 mg/kg per day of prednisone or 
equivalent).  Taper as appropriate.  
• Manage cardiac symptoms according to 
standard of care and with guidance from 
cardiology. Consider cardiac MRI and 
myocardial biopsy for diagnosis.  
• Timely cardiology referral . 
Incyte Corporation  Page 40 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  [IP_ADDRESS].  Immune -Mediated Nervous System Events  
Immune -mediated nervous system events, including Guillain -Barre syndrome, autoimmune 
enceophalitis, myasthenia gravis, autonomic neuropathy, and transverse myelitis , can occur.  
Monitor participants for these immune -mediated nervous system events and exclude other 
causes.  Recommendations for the management of immune -mediated nervous system events  are 
shown in  Table  19. 
Table  19: Recommended Approach for Handling Immune -Mediated Nervous System 
Events  
Study Drug –Associated 
Nervous System Events  Withhold/Discontinue  
Study Treatment  Supportive Care  
Grade 1  No action.  Intervention not indicated.  
Grade 2  Withhold study treatment until ≤ 
Grade 1.  • Neurology consultation is recommended 
for all neurologic irAEs ≥  Grade  2. 
• Treatment with systemic corticosteroids 
should be initiated (initial dose of 
1-2 mg/kg per day of prednisone or 
equivalent).  Taper as appropriate.  
• For Grade 2 transverse myelitis consider 
permanent discontinuation.  
• Manage symptoms according to standard 
of care and with guidance from 
neurology.  Grade 3 or 4  Permanently discontinue  study 
treatment.  
[IP_ADDRESS].  Other Immune -Mediated Adverse Events  
Recommendation s for management of immune -mediated adverse events not specified above are 
shown in Table  20. 
Table  20: Recommended Approach to Handling Other Immune -Mediated Adverse 
Events  
Study Drug -Associated 
Immune -Mediated Adverse 
Events  Withhold/Discontinue  
Study Treatment  Supportive Care  
Grade 1  No action.  None  
Grade 2 or Grade 3 based on 
severity and type of reaction  Withhold until ≤ Grade 1.  Based on severity of AE, administer 
corticosteroids.  
Recurrent Grade 3 or 
Persistent Grade 2 and 
Grade  3 Permanently discontinue study 
treatment.  
Grade 4 (excluding 
endocrinopathies)  
Incyte Corporation  Page 41 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  6.5.3.  Permanent Discontinuation of Study Drug  Due to Toxicity  
The occurrence of unacceptable toxicity not caused by [CONTACT_89188] .  Unacceptable toxicity is defined as follows:  
• Occurrence  of an AE that is related to study treatment that, in the judgment of the 
investigator or the sponsor 's medical monitor, compromises the participant 's ability to 
continue study -specific procedures or is considered to not be in the participant 's best 
intere st. 
• Persistent AE requiring a delay of therapy for more than 12 weeks . 
• Any AE defined in the dose modifications management guidelines ( Section  6.5) 
requiring the study treatment be discontinued . 
A complete list of study treatment discontinuation reasons and procedures  is found in Section  7. 
6.6. Conc omitant Medications  and Procedures  
All concomitant medications and  treatments (including over -the-counter or prescription 
medicines, vitamins, vaccines, and/or herbal supplements) and medical procedures must be 
recorded in the eCRF.  Any medication or proc edure received from signing the ICF to [ADDRESS_98054],  will be recorded in the eCRF.  Any addition, deletion, or change in the 
dose of these m edications will also be recorded.  Concomitant medications administered for the 
management of SAEs should be recorded regardless of when they are pr ovided.  Concomitant 
medications and/or procedures administered to a participant for  manage ment of  a medical 
condition during the study will also be recorded in the eCRF.  The medical monitor should be 
contact[CONTACT_31182].  
6.6.1.  Permitted Medications and Procedures  
Highly active antiretroviral therapy s hould be continued for participants who are known to be 
HIV-positive .  Recommended supportive measures for specific toxicities are described above.  
Growth factors, bisphosphonates, anticoagulants, and transfusional support will also be permitted  
at any po int in the study . 
Premedication  with an antipyretic (eg, acetaminophen /paracetamol ) and a  histamine blocker 
should be considered for participants who have had previous systemic reactions to protein 
product infusions or when recommended according to institu tional policy . 
6.6.2.  Prohibited Medications and Procedures  
• Other anticancer therapi[INVESTIGATOR_014], including investigational treatments.  
• Immunosuppression in excess of physiologic maintenance corticosteroid doses (with 
the exception of acute treatment for an AE).   The use o f corticosteroids should be 
limited to the extent possible.  Chronic doses of corticosteroids in excess of 10 mg 
daily of prednisone or equivalent are prohibited other than for the management of 
drug-related adverse experiences.   Steroids may be employed i n the treatment of 
suspected INCMGA [ZIP_CODE]-associated immune -inflammatory or autoimmun e AEs in 
consultation with the s ponsor.  
Incyte Corporation  Page 42 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  • Live vaccines within [ADDRESS_98055] dose of 
study drug.  
Note:   Examples of live vaccines include, but are not limited to, the following:  
measles, mumps, rubella, chicken pox/zoster, yellow fever, rabies, Bacillus Calmette –
Guérin , and typhoid vaccine.  Seasona l influenza vaccines for injection are generally 
killed virus vaccines and are allowed; however, int ranasal influenza vaccines 
(eg, FluMist®) are live -attenuated vaccines and are not allowed.  
• Probiotic dietary supplements  
6.7. Treatment After the End of the Study  
Once a participant  has discontinued study treatment , no further treatmen t will be provided in this 
study.  Participant s who discontinue are eligible to enter the follow -up period to be evaluated for 
safety  and survival.  Any participant s entering the  follow -up period for any reason other than PD 
will continue to be evaluated for disease status according to the scheduled assessments found in 
Table  3. 
Incyte Corporation  Page 43 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  7. DISCONTINUATION OF S TUDY TREATMENT  AND 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL  
7.1. Discontinuation of Study Treatment  
7.1.1.  Reasons for Discontinuation  
Participants must  be withdrawn from study treatment for the following reasons:  
• Disease progression.  
• Unacceptable toxicity as noted in Section  [IP_ADDRESS] . 
• Consent is withdrawn . 
Note:   Consent withdrawn means that the participant has explicitly indicated  that they 
do not want to be followed any longer; in this case no further data, except data in 
public domain, may be solicited from or collected on the participant .  Participants 
may choose to discontinue study treatment and remain in the study to be follo wed for 
progression and survival.  
• Further participation would  be, based on the medical judgment of the investigator, 
injurious to the hea lth or well -being  of the participant . 
• The study is terminated by [CONTACT_456].  
• The study is terminated by [CONTACT_89189], IRB, or IEC.  
• The participant  becomes pregnant (see Section  9.7). 
A participant  may be discontinued from study treatment as follows:  
• If a participant is noncompliant with study procedures or treatment  administration , 
and in the judgment of the investigato r the participant  is not receiving a clinical 
benefit.  When possible, the spo nsor should be informed and/or consulted.  
• The participant achieves a confirmed CR after at least 6 months of treatment .  
Participants may continue on study treatment after confir mation of CR per the 
discretion of the investigator if they feel the participant may gain additional benefit.  
Note:  The participant should be continue to be followed for disease status and 
survival after discontinuation of treatment.  
7.1.2.  Discontinuation Pro cedures  
In the event that the decision is made to permanently discontinue the study treatment , the EOT  
visit should be conducted .  Reasonable efforts should be made to have the participant return for a 
follow -up visit .  These visits are described in  Table  3.  The last date of the last dose of study 
treatment  and the reason for discontinuation of study treatment will be recorded in the eCRF.  
If a pa rticipant is discontinued from study treatment:  
• The study monitor or sponsor must be notified.  
• The reason(s) for withdrawal must be documented in the participant 's medical record 
and the primary reason for withdrawal must be included in the eCRF.  
Incyte Corporation  Page 44 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  • The EOT visit should be performed.  
• The date of the EOT visit should be recorded in the IRT. 
• Participants must be followed for safety for [ADDRESS_98056] study treatment , or 
until study treatment –related toxicities resolve, return to baseline, or are deemed 
irreversible, whichever is longest.  
If the participant discontinues study treatment and actively withdraws consent for collection of 
follow -up data (safety follow -up or disease assessment), then no additional data collection 
should occur; however, particip ants will have the option of withdrawing consent for study 
treatment and further assessments but allowing survival follow -up. 
7.2. Participant Withdrawal From the Study  
A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance, or 
administrative reasons.  
If the participant withdraws consent for disclosure of future information, the sponsor may retain 
and continue to use any data collected before such a withdrawal of consent.  
If a participant withdraws consent from the study, he/she may request destruction of any samples 
taken and not tested, and the investigator must document this in the site study records.  
See Table  [ADDRESS_98057] to follow -up if he /she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298] . 
The following actions must be taken if a participant fails to return to the clinic for a  required 
study visit:  
• The site must attempt to contact [CONTACT_89190] t wishes to and/or 
should continue in the study.  
• Before a participant is deemed lost to follow -up, the investigator or designee must 
make every effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary, a certified letter to the participant 's last known mailing address 
or local equivalent methods) .  These contact [CONTACT_21457] 's medical record.  
• Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study . 
Incyte Corporation  Page 45 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  8. STUDY ASSESSMENTS AN D PROCEDURES  
8.1. Administrative and General Procedures  
8.1.1.  Informed Consent Process  
• The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally authorized repre sentative and answer all questions 
regarding the study.  
− Informed consent must be obtained before any study -related procedures are 
conducted, unless otherwise specified by [CONTACT_89191].  
− Informed consent must be obtained using the IRB/IEC -approved version in  a 
language that is native and understandable to the participant.  A template will be 
provided by [CONTACT_3552].  The sponsor or its designee must review 
and acknowledge the site -specific changes to the ICF template.  The ICF must 
include a s tatement that the sponsor or its designee and regulatory authorities have 
direct access to participant records.  
− The ICF must contain all required elements and describe the nature, scope, and 
possible consequences of the study in a form understandable to th e study 
participant.  
• Participants must be informed that their participation is voluntary.  Participants or 
their legally authorized representative will be required to sign a statement of informed 
consent that meets the applicable requirements and regulatio ns for the countries in 
which the study is being conducted as well as the IRB/IEC or study center.  
• The participant must be informed that his/her personal study -related data will be used 
by [CONTACT_89192].  The lev el of disclosure 
must also be explained to the participant.  
• The participant must be informed that his/her medical records may be examined by 
[CONTACT_78582], by [CONTACT_6667]/IEC members, and by [CONTACT_9326].  
• The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study and the date the written 
consent was obtained.  The authorized p erson obtaining the informed consent must 
also sign the ICF.  
• Participants must provide consent to the most current version of the ICF(s) during 
their participation in the study.  
• A copy of the ICF(s) must be provided to the participant or the participant 's legally 
authorized representative.  
Participants who are rescreened are required to sign a new ICF.  
Incyte Corporation  Page 46 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL   
 
 
 
 
 
 
8.1.2.  Screening Procedures  
Screening is the interval between signing the ICF and enrollment  in the study (Cycle  1 Day  1).  
Screening may not exceed 28 days.  Assessments required to demonstrate eligibility will be 
performe d during the screening period.  
Procedure s conducted as part of the participant 's routine clinical management (such as laboratory 
analyses)  before signing the ICF may be used for screening or baseline purposes , provided the 
procedure meets the Protocol -defined criteria and has been performed with in [ADDRESS_98058] will indicate 
the date and time of the next visit and will also inform the participant about visit -specific 
procedures.  
8.1.5.  Demography and Medical History  
[IP_ADDRESS].  Demographics and General Medical History  
Demographic data  and general medical history will be collected at screening  by [CONTACT_89193], race, ethnicity, medical and surgical history, 
and current illnesses.  Medical history will include relevant medical or su rgical treatment 
considered to be clinically significant by [CONTACT_093].  

Incyte Corporation  Page 47 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  [IP_ADDRESS].  Disease Characteristics and Treatment History  
A disease -targeted medical and treatment history will be collected at screening .  Details 
regarding the participant 's malignancy under study, including date of diagnosis, initial and 
current cancer stage, tumor histology, and relevant disease characteristics, and prior treatments, 
including systemic treatments, radiation, and surgical procedures, will be recorded.  
8.2. Efficacy Assessmen ts 
Objective assessment of disease status will be evaluated according to RECIST v1.1 
(Eisenhauer  et al 2009 ) by [CONTACT_89170].   Participants should be actively monitored for RECIST 
response up until they start new anticancer th erapy or have PD.  
  
 
The disease response assessments according to 
RECIST  v1.1  by [CONTACT_89194].  
Efficacy assessments  of response  should be performed according to schedule found in Table  3.  
Scans should follow calendar days and remain on the 8 -week schedule  (± 7 days) , 
established on Cycle [ADDRESS_98059] 12 months and then 
every 12 weeks th ereafter  (ie, the schedule should switch to every 12 weeks after the Week 56 
scan) .  For participants who discontinue study treatment for reasons other than disease 
progression, every effort should be made to continue monitoring their disease status by  
[CONTACT_89195] -up schedule.  
Participants who continue study participation in the follow -up period without experiencing 
disease progression will continue to have efficacy assessments every 12 weeks (± 7 days) from 
the previous  scan until they complete participation in the study, start a new anticancer therapy, 
experience disease progression , or death . 
8.2.1.  Tumor Imaging  
Disease assessment and tumor response to study drug will be evaluated according to 
RECIST  v1.1 guidelines (Eisenhauer et al 2009 ) as described in Appendix  B.  All imaging  must 
be submitted to the central imaging vendor for independent review.  The recommended method 
for measuring and following tumor burden will be CT scan, which sh ould be performed using 
consistent techniques and facilities.  Alternative modalities such as MRI may be substituted for a 
CT scan at the discreti on of the investigator, provided that the same modality is used throughout 
the study and the methodology is consistent with RECIST v1.1.  Initial tumor imaging must be 
performed within [ADDRESS_98060], abdomen, and pelvis are required for all subjects.  Additional 
imaging of anatomical sites (ie, head , neck,  and extremities ) should be performed as applicable if 
participant has suspected disease in those areas.   Computed tomography or MRI scan of the brain 

Incyte Corporation  Page 48 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  will be performed at screening if there are signs or symptoms suggesting that the participant has 
disease involvement in the CNS.  
8.2.2.  Photographic Analysis of Skin Lesions  
Photographic imaging of skin tumors that are being followed as target lesions is required and 
should follow the schedule of events for clinical tumor assessment.  Instructions are provided i n 
the Photography User Manual . 
  
 
 
 
  
 
 
 
 
 
 
 
8.2.4.  Health Economics  
Not applicable . 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 

Incyte Corporation  Page 49 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL    
 
 
8.3. Safety Assessments  
See Section  6.5 and refer to the American Society of Clinical Oncology and European Society 
for Medical Oncology Clinical Practice Guideline s (Brahmer et al 2018 , Haanen  et al 2017 ) for 
management guidelines regarding of known or potential AEs and toxicities.  
Safety will be monitored by [CONTACT_89196] 's study physician and 
pharmacovigilance physic ian.  Regularly scheduled meetings/teleconferences will be held for 
review of AEs by [CONTACT_456] 's study physician and pharmacovigilance physicia n with 
partici pating investigators.  
8.3.1.  Adverse Events  
Adverse events will be monitored from the time the participant signs the ICF  until at least 
[ADDRESS_98061].  Adverse events that begin or worsen after informed consent should be 
recorded on the Adverse Events Form in the eCRF  regardless of the assumption of a causal 
relationship with the study treatment(s) .  Conditions that were already present at the time o f 
informed consent should be recorded on the Medical History Form in the eCRF .  Adverse events 
(including laboratory abnormalities that constitute AEs) should be described using a diagnosis 
whenever possible rather than by [CONTACT_89197] s ymptoms.   Adverse events 
judged to be potentially immune -related should be described on the appropriate eCRF.   The 
severity of AEs will be determined using CTCAE v5.0.  
Adverse events will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, 
surrogate, or the participant 's legally authorized representative) .  The investigator and any 
qualified designees are responsible for detecting, documenting, and recording events that meet 
the definition of an AE or SAE and remain responsible fo r following -up on AEs that are serious, 
considered related to the study treatment /procedures, or that caused the participant to discontinue 
the study treatment .  Care will be taken not to introduce bias when detecting AEs and/or SAEs .  
Open -ended and nonle ading verbal questioning of the participant, such as "How are you 
feeling? " is the preferred method to inquire about AE  occurrences .  Adverse events may also be 
detected when they are volunteered by [CONTACT_89198], or through physical examination s, laboratory test s, or other assessments .  The definition, 
reporting, and recording requirements for AEs are described in Section  9. 
All SAEs will be recorded and reported to the sponsor or designee within 24 hours .  The 
investigator will submit any updated SAE data to the sponsor within 24 hours of it being 
available.  
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts .  All SAEs, and nonserious AEs of special int erest (as defined in 
Section  9.5), will be followed until resolution, stabilization, the event is otherwise explained, or 
the participant is lost to follow -up (as defined in Section  7.3). 

Incyte Corporation  Page [ADDRESS_98062] be performed by a medically qualified individual , such as a licensed 
physician, physician 's assistant, or an advanced registered nurse practit ioner, as local law 
permits .  Abnormalities identified after signing the ICF constitute an AE if they are considered 
clinically meaningful, induce clinical signs or symptoms, require concomitant therapy, or require 
changes in study treatment  (with the exception of abnormalities associated with  clinical  disease 
progression) .  Investigators should pay special attention to clinical signs related to previous 
serious illnesses.   
At the screening visit, a comprehensive physical examination should b e conducted .  The 
comprehensive physical examination will include height (only at screening),  weight, and 
assessment(s) of the following organ or body systems:  skin; head, eyes, ears, nose, and throat; 
thyroid; lungs; cardiovascular system; abdomen (liver , spleen); extremities; and lymph nodes; as 
well as a brief neurological examination.  
During the study, participants will be assessed by [CONTACT_89199].  These assessments should be an ev aluation as 
indicated by [CONTACT_89200], AEs, or other findings.   Weight will also be assessed at each 
study visit.  
In addition, a disease -related clinical assessment should be performed at each study visit.  
8.3.3.  Vital Signs  
Vital sign measurements  includ ing blood pressure, O2 saturation, pulse, respi[INVESTIGATOR_697], and 
body temperature  should to be taken prior to the blood collection for laboratory analyses .  Blood 
pressure and pulse will be taken with the participant in the recumbent, semirecumbent, or sitt ing 
position after [ADDRESS_98063] dose of study treatment constitute an AE if they are considered clinically 
meaningful, induce clinical signs or symptoms, require concomitant therapy, or require changes 
in study treatment.  
8.3.4.  Eastern Cooperat ive Oncology Group Performance Status  
The ECOG performance status score will be assessed according to the criteria in Table  21. 
Table  21: Eastern Cooperative Group Performance Status Scoring  
Grade  ECOG Performance Status  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature, eg, light house work, office work  
2 Ambulatory and capable of all self -care but unable to carry out any work activities; up and about more 
than 50% of waking hours  
3 Capable of only limited self -care; confined to bed or chair more than 50% of waking hours  
4 Completely disabled; cannot carry on any self -care; totally confined to bed or chair  
5 Dead  
Source:  Oken et al [ADDRESS_98064].  
Electrocardiogram s should be performed before  study drug infusion and will be interpreted by 
[CONTACT_89201] .  Additional ECGs 
may be performed as clinically indicated to manage partici pant safety .  The decision to include 
or exclude a participant or withdraw a participant from the study treatment based on an ECG 
flagged as "Abnormal, Clinically Significant " is the responsibility of the investigator, in 
consultation with the sponsor 's medical monitor, as appropriate .  Clinically notable abnormalities 
that are considered clinically significant in the judgment of the investigator are to be reported as 
AEs. 
8.3.6.  Laboratory Assessments  
Clinical safety laboratory analyses (ie, blood chemistries, he matology assessments, coagulation 
tests, endocrine function, fasting lipid panel, and urinalysis) will be performed in certified local 
laborator ies associated with study sites .  Blood and urine samples will be collected for laboratory 
analyses during study  visits, before  study treatment administration, according to the schedule in 
Table  3.  Participants  are expected to fast prior to blood collection during visits that include lipid 
panel analysis.  The laboratory analytes to be evaluated are found in Table  22.  Additional testing 
may be required by [CONTACT_89202].  Additional tests may also be 
performed if clinically indicated.  
Analysis by [CONTACT_89203] –related decisions are acceptable using a 
certifi ed laboratory available to the investigative site.  The investigative site will enter the results 
and normal ranges into the eCRF from any local laboratory analysis.  
Further detailed information regarding collection, processing, and shippi[INVESTIGATOR_89154].  
Clinically significant abnormal laboratory findings are those that are not associated  with the 
underlying disease, unless judged by [CONTACT_41411] 's con dition .  All abnormal laboratory values considered clinically significantly up to  
[ADDRESS_98065] be repeated before  the 
initial study treatment  administration on Cycle 1 Day 1 .  After Cycle 1, predose lab oratory 
procedures can be conducted up to 72 hours before study treatment administration, and results 
Incyte Corporation  Page 52 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  should be reviewed by [CONTACT_89204] a 
new cycle of treatment is initiated.  
A final laboratory a nalysis is required during the 28 -day follow -up safety visit.  These labs 
should only be performed at the EOT visit if the EOT visit is also serving as the 28 -day safety 
visit.  
 
 
[IP_ADDRESS].  Pregnancy Testing  
Serum pregnancy tests are required for all women of childbearing potential during screening and 
either EOT or the  safety  follow -up visit [ADDRESS_98066].  

Incyte Corporation  Page 53 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Table  22: Required Laboratory Analytes  
Blood  Chemistries  Hematology  Urinalysis With 
Microscopic Examination  Coagulation  Pregnancy Testing  
Albumin  
Alkaline phosphatase  
ALT  
AST  
Amylase  
Bicarbonate or CO [ADDRESS_98067] bilirubin (if total bilirubin 
is elevated above ULN)  
Total protein  
Uric acid  Complete blood count, 
including:  
• Hemoglobin  
• Hematocrit  
• Platelet count  
• Red blood cell count  
• WBC count  
 
Differential count, including:  
• Basophils  
• Eosinophils  
• Lymphocytes  
• Monocytes  
• Neutrophils  
 
Absolute values must be 
provided for:  
• WBC differential 
laboratory results  Color and appearance  
pH and specific gravity  
Bilirubin  
Glucose  
Ketones  
Leukocytes  
Nitrite  
Occult blood  
Protein  PT 
PTT or aPTT  
INR Female participants of 
childbearing potential 
require a serum 
pregnancy test at 
screening and EOT, or 
[ADDRESS_98068] will be 
acceptable prior to 
receiving study treatment 
on Day 1 of each 
treatment cycle.  
Lipid Panela Endocrine Function   
 
 
Total cholesterol  
Triglycerides  
LDL  
HDL  TSH  
T4/FT4  
T3/FT3   
 
SARS -CoV -2 
SARS -CoV -2 testing during 
the COVID -19 pandemic, as 
per country, local, 
institution's requirements  
Note:  Additional tests may be required, as agreed upon by [CONTACT_86206], based on emerging safety data.  
a Participants are required to fast prior to blood collection for lipid panel analysis.  

Incyte Corporation  Page [ADDRESS_98069] dates and times of the PK blood collection will be recorded in the 
eCRF.  Instructions for sample preparation and shippi[INVESTIGATOR_22016] t he Laboratory 
Manual.  
Table  23: Pharmacokinetic and Antidrug Antibody Serum Blood Sample Timing  
Study Visit  Assessment  Timing of Sample  
Cycle [ADDRESS_98070]  INCMGA00012 
infusion ( ± 10 minutes)  
[ADDRESS_98071] INCMGA00012 
infusion (±  15 minutes)  
Cycle [ADDRESS_98072] INCMGA00012 
infusion (± 10 minutes)  
[ADDRESS_98073] INCMGA00012 
infusion (±  15 minutes)  
Cycle 7 Day 1  PK Preinfusion  

Incyte Corporation  Page 55 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  

Incyte Corporation  Page 56 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  8.6. Unscheduled Visits  
Unscheduled study visits may occur at any time if medically warranted.  Any assessments 
performed at those visits should be recorded in the eCRF.  
8.7. End of Treatment  and/or Early Termination  
Once a  participant permanently discontinues study  treatment , the EOT visit should be conducted , 
and the data should be entered in the EOT visit in the eCRF .  If the EOT visit coincides with a 
regular study visit, the EOT evaluatio ns will supersede those of that scheduled visit.  Should  
study treatment discontinuation occur ≤  21 days after the final dose of study treatment, a 28-day 
safety follow -up visit is required and should be conducted according to Table  3.  If the EOT visit 
occurs > [ADDRESS_98074] study treatment, only a single EOT/[ADDRESS_98075] actively withdrawn consent  for any further parti cipation in the study , should be 
encouraged to participate in the follow -up period . 
8.8.1.  Safety Follow -Up 
The safety follow -up period starts once the participant discontinues study treatment.  
Approximately 28 (± 7) days a fter the final dose of study drug, participants are to attend a 
clinical visit for a safety evaluation.  During this visit, blood will be collected  for safety 
laboratory analysis,  and other safety assessment s, such as a physical exam ination  and recording 
AEs and concomitant medications , will be performed as described in Table  3.  Participants will 
be followed for AEs up to [ADDRESS_98076]-Treatment Disease Follow -Up 
Participants who discontinue study treatment for a reason other than disease progression will 
move into the disease status follow -up period and should be assessed according to the schedule 
of events  until:  
• The start of new anti cancer  therapy.  
• Disease  progression.  
• Death.  
• The end of the study.  
• Participant is lost to follow -up. 
8.8.3.  Survival Follow -Up 
Once a participant has received the last dose of study treatment , has confirmed disease 
progression, or starts a new anticancer therapy, the participant moves i nto the survival follow -up 
period and should be contact[CONTACT_5143], email, or visit at least every [ADDRESS_98077].  
For partic ipants having entered the survival follow -up period of the study, the site will use 
continuing participant records to supply data on subsequent treatment regimens, tumor 
assessments (if discontinued treatment for a reason other than disease progression), a nd OS in 
the eCRF .  For participants who do not intend to return to the study investigator for their ongoing 
care, follow -up should be maintained by [CONTACT_89205], patient records, and public 
records/databases (as permitted by [CONTACT_44896]) at intervals of no longer than 
12 weeks . 
Incyte Corporation  Page 58 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  9. ADVERSE EVENTS:  DEFINITIONS AND PROC EDURES FOR 
RECORDING, EVALUATIN G, FOLLOW -UP, AND RE PORTING  
9.1. Definition of A dverse Event 
Adverse Event Definition  
• An AE is any untoward medical occurrence associated with the use of  a drug in humans, whether or 
not considered drug -related.  
• An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease (new or exacerbated) temporally associated with the use of study 
treatment.  
Events Meeting  the A dverse Event Definition  
• Any safety assessments (eg, ECG, vital signs measurements), including those that worsen from 
baseline, considered clinically significant in the medical and scientific judgment of the investigator 
(ie, not related to progression of underlying disease).  
• Abnormal  laboratory test results constitute an AE if they are considered clinically meaningful, induce 
clinical signs or symptoms, require concomitant therapy, or require changes in study drug.   
Wheneve r possible, a diagnosis (eg, anemia, thrombocytopenia) should be recorded in the eCRF 
rather than the abnormal lab result (eg, low hemoglobin, platelet count decreased).  
• Exacerbation of a chronic or intermittent pre -existing condition including either an i ncrease in 
frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after study treatment administration even though they may 
have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected  drug-drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment or a 
concomitant medication .  Overdose per se will not be reported as an AE/SAE unless it is an 
intentional overdose ta ken with possible sui cidal/self -harming intent .  Such overdoses should be 
reported regardless of sequelae.  
• "Lack of efficacy " or "failure of expected pharmacological action " per se will not be reported as an 
AE or SAE.  Such instances will be captured in the efficacy assessments.  However, the signs, 
symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported as an AE or SAE 
if they fulfill the definit ion of an AE or SAE.  
Incyte Corporation  Page 59 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Events NOT  Meeting the A dverse Event Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments that are 
associated with the underlying disease, unless judged by [CONTACT_89206] e severe than 
expected for the participant 's condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant 's condition  or 
considered to be treatment -related by [CONTACT_093] . 
• Efficacy endpoints as outlined in Section  3 will not be reported as AE/SAEs, specifically, any event 
that is related to disease progression of the cancer under study.  Unblinded aggregated efficacy 
endpoint events and safety data will be monitored to ensure the safety of the participant s in the study .  
Any suspected endpoint that upon review is not progression of the cancer under study will be 
forwarded to Incyte Pharmacovigilance as a SAE within 24 hours of determination that the event  is 
not progression of the cancer under study.  
• Medical or surgical procedure (eg, endoscopy, appendectomy):  the condition that leads to the 
procedure is the AE  if it occurred after signing informed consent .  If present before entering the 
study, the condi tion should be captured as medical history.  
• Situations in which an untoward medical occurrence did not occur (social and/or convenience 
admission to a hospi[INVESTIGATOR_307]).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or dete cted at 
the start of the study that do not worsen.  
9.2. Definition of S erious Adverse Event 
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due to 
progression of disease).  
A Serious Adverse Event is defined as any untoward medical occurrence that, at any dose:  
a.  Results in death  
b.  Is life -threatening  
The term 'life-threatening ' in the definition of 'serious ' refers to an adverse drug experience that places 
the participant , in the opi[INVESTIGATOR_89155], at immediate risk of death from the adverse 
experience as it occurred.  This does not include an adverse drug experience that, had it occurred in a 
more severe for m, might have caused death . 
c.  Requires inpatient hospi[INVESTIGATOR_12993], hospi[INVESTIGATOR_19949] (usually involving at least an 
overnight stay) at the hospi[INVESTIGATOR_89156]/or treatment that would not have 
been appropriate in the physician 's office or outpatient setting .  Complications that occur during 
hospi[INVESTIGATOR_1084] .  If a complication prolongs hospi[INVESTIGATOR_89157], 
the event is serious .  When in doubt as to whether "hospi[INVESTIGATOR_059] " occurred or was necessary, the AE 
should be considered serious.  
Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen from baseline is 
not considered an AE.  
Incyte Corporation  Page 60 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  d.  Results in persistent or significant disability/incapacity  
• The term disability means a substantial disruption of a person 's ability to conduct normal life 
functions.  
• This definition is not intended to include experiences of relatively minor medical significance , such 
as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma 
(eg, sprained ankle) , that may interfere with or prevent everyday life functions but do not constitute a 
substantial disruption.  
e.  Is a congenital anomaly/birth defect  
f. Other situations  (Important Medical Event)  
An event that may not result in death, be immediately life -threatening, or require hospi[INVESTIGATOR_059], but 
may be considered serious when, based on appropriate medical judgment, the event may jeopardize the 
participant and may require medical or surgical inte rvention to prevent one of the outcomes listed in 
the above definition.   Examples of such events include invasive or malignant cancers  (excluding the 
disease[s] under study in oncology protocols) , intensive treatment in an emergency department  or at 
home f or allergic bronchospasm, blood dyscrasias , or convulsions that do not result in hospi[INVESTIGATOR_059], 
or development of drug dependency or drug abuse.  
9.3. Recording and Follow -Up of Adverse Events and/or S erious Adverse 
Events 
Adverse Event and S erious Adverse Event Recording  
• An AE/SAE that begins or worsens after informed consent is signed should be recorded on the 
Adverse Event  Form in the eCRF .  Conditions that were present at the time informed consent was 
given should be recorded on the Medical History Form in the eCRF.  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation 
(eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics reports) related to the event.  
• The investigator (or delegate) will then record al l relevant AE/SAE information in the eCRF.  
• It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914] 's medical records in 
lieu of completing  the AE eCRF page.  
• There may be instances when copi[INVESTIGATOR_89158] e requested .  In this case, 
all participant identifiers, with the exception of the participant number, will be redacted on the copi[INVESTIGATOR_89159].  
• The investigator will attempt to establish a diagnosis of the event based on sig ns, symptoms, and/or 
other clinical information .  Whenever possible, the diagnosis (not the individual signs/symptoms) 
will be documented as the AE/SAE .  When a clear diagnosis cannot be identified, each sign or 
symptom should be reported as a separate AE /SAE . 
To the extent possible, each AE /SAE  should be evaluated to determine:  
• The severity grade (CTCAE v5.0 Grade 1 to 5).  See below for further instructions on the assessment 
of intensity.  
• Whether there is at least a reasonable possibility that the AE is r elated to the study treatment    
suspected (yes) or not suspected (no) .  See below for further instructions on the assessment of 
causality.  
• The start and end dates, unless unresolved at final follow -up. 
• The action taken with regard to study drug  as a result  of the AE/SAE (s). 
Incyte Corporation  Page 61 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  • The event outcome (eg, not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequelae, fatal, unknown).  
• The seriousness, as per the SAE definition provided in Section  9.2. 
• The action taken with regard to the event . 
Note:   If an AE is treated with a concomitant medication or nondrug therapy, this action should be 
recorded on Adverse Event Form and the treatment should be specified on the appropriate eCRF 
(eg, Prior/Concomitant Medications , Procedures and Non drug Therapy ). 
Assessment of Intensity  
The severity of AEs will be assessed using CTCAE v5.0 Grades 1 through 5 .  If an event is not 
classified by [CONTACT_3989], the severity of the AE will be graded according to the scale below to estimate the 
grade of severity:  
The investigato r will make an assessment of intensity for each AE and SAE reported during the study 
and assign it to 1 of the following categories:  
• Grade 1:   Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment  
not indicated.  
• Grade 2:   Moderate; minimal, local, or noninvasive treatment  indicated; limiting age appropriate 
activities of daily living.  
• Grade 3:   Severe or medical significant but not immediately life -threatening; hospi[INVESTIGATOR_8942];  disabling; limiting self -care activities of daily living.  
• Grade 4:   Life-threatening consequences; urgent treatment  indicated.  
• Grade 5:   Fatal.  
Assessment of Causality  
• The investigator is obligated to assess the relationship between study treatment and each occurrence 
of each AE/SAE .   
• A "reasonable possibility " of a relationship conveys that there are facts, evidence, and/or arguments 
to suggest a causal relationship, rather than that a relationship cannot be ruled out.  
• The investigator will use clinical judgment to determine the relationship.  
• The investigator will also consult the Reference Safety Information  in the IB and/or Product 
Information, for marketed products, in his/her assessment.  
• Alternative causes, such as underlying disease(s), conc omitant therapy, and other risk factors, as well 
as the temporal relationship of the event to study treatment administration , will be considered and 
investigated.  
• For each AE/SAE, the investigator must  document in the medical notes that he/she has reviewed  the 
AE/SAE and has provided an assessment of causality.  
• With regard to assessing causality of SAEs:  
− There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report .  However,  the causality  assessment is one of the criteria 
used when determining regulatory reporting requirements.  Therefore,  it is very important that 
the investigator always make an assessment of causality for every event before the initial 
transmission of the SAE.  
− The invest igator may change his/her opi[INVESTIGATOR_9242] -up information and 
send a follow -up SAE report with the updated causality assessment.  
Incyte Corporation  Page 62 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Follow -Up of A dverse Events and S erious Adverse Events 
• The investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by [CONTACT_89207]/or causality of the AE or SAE as fully as possible .  This may include additional laboratory tests 
or investigations, histopathological examinations, or consultation with other health care 
professionals.  
• New or updated information will be recorded in the originally completed eCRF.  
• Any updated SAE data will be subm itted to the sponsor (or designee) within 24  hours of receipt of 
the information.  
• Once an AE is detected, it should be followed until it has resolved or until it is judged to be 
permanent; assessment should be made at each visit (or more frequently if nece ssary) of any changes 
in severity, the suspected relationship to the study drug, the interventions required to treat the event, 
and the outcome.  
• When the severity of an AE changes over time for a reporting period (eg, between visits), each 
change in severi ty will be reported as a separate AE until the event resolves . 
9.4. Reporting of S erious Adverse Events 
Regardless of suspected causality (eg, relationship to study  treatment  or study procedure [s]), all 
SAEs occurring after the participant has signed the ICF t hrough [ADDRESS_98078] be reported to the sponsor (or designee) within 24 hours  of learning of its occurrence, 
unless otherwise specified by [CONTACT_89191] .  The investigator will submit any updated SAE data 
to the sponsor (or designee) within 24 hours of it being available . 
Investigators are not obligated to actively seek AE or SAE information after conclusion of the 
study participation .  However, if the investigator learns of any SAE, including a death, at any 
time after a participant has been discharged from the study, and he/she considers the event to be 
reasonably related to the st udy treatment or study participation, the investigator must notify the 
sponsor (or designee) within 24 hours of becoming aware of the event . 
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts .  All SAEs, and nonserious AEs of special interest (as defined in 
Section  9.5), will be followed until resolution, stabilization, the  event is otherwise explained, or 
the participant is lost to follow -up (as defined in Section  7.3). 
Prompt notification by [CONTACT_11012] a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a study 
treatment under clinical investigation are met . 
If the SAE is not documented in the IB for the study drug (new occurrence) and is thought to be 
related to the sponsor 's study drug, the sponsor or its designee may urgently require further 
information from the investigator for reporting to health authorities .  The sponsor or its design ee 
may need to issue an Investigator Notification to inform all investigators involved in any study 
with the same drug that this SAE has been reported .  Suspected unexpected serious adverse 
reactions  will be collected and reported to the competent  authorit ies and relevant ethics 
committees in accordance with Directive 2001/20/EC, or as per national regulatory requirements 
in participating countries.   The sponsor has a legal responsibility to notify both the local 
Incyte Corporation  Page 63 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  regulatory authority and other regulatory ag encies about the safety of a study treatment under 
clinical investigation .  The sponsor will comply with country -specific regulatory requirements 
relating to safety reporting to the regulatory authority, IRB/IEC , and investigators.  
Investigator safety re ports must be prepared for suspected unexpected serious adverse reactions  
according to local regulatory requirements and sponsor policy and forwarded to investigators as 
necessary.  
An investigator who receives an investigator safety report describing a SAE  or other specific 
safety information (eg, summary or listing of SAEs) from the sponsor will review and then file it 
along with the IB and will notify the IRB/IEC, if appropriate according to local requirements.  
Serious Adverse Event Reporting  
• Information  about all SAEs is collected and recorded on the Adverse Event Form in the eCRF . 
• The investigator must also complete the Incyte Serious Adverse Event Report Form, in English .  
Refer to the Incyte Reference Guide for Completing the Serious Adverse Event Rep ort Form.  
• Facsimile or email transmission of the Serious Adverse Event  Report Form  is the preferred method 
to transmit this information to the  PhV/designee .  The contact [CONTACT_89208] 's 
study -specific representatives is listed in the Investiga tor Site Binder  provided to each site .  The 
original copy of the Serious Adverse Event  Report Form and the confirmation sheet must be kept at 
the study site.  
• Follow -up information is recorded on an amended or new Serious Adverse Event  Report Form, with 
an indication that it is follow -up to the previously reported SAE and the date of the original report .  
The follow -up report should include information that was not provided on the previous Serious 
Adverse Event  Report Form, such as the outcome of the event (eg, resolved or ongoing), treatment 
provided, action taken with study drug because of the SAE (eg, dose reduced, interrupted, or 
discontinued), or participant  disposition (eg, continued or withdrew from study participation) .  Each 
recurrence, complication, or progression of the original event should be reported as follow -up to that 
event, regardless of when it occurs.  
• In rare circumstances and in the absence of facsimile or computer equipment, notification by 
[CONTACT_89209] a copy of the Incyte Serious Adverse Event  Report Form  sent by 
[CONTACT_22855] .  Initial notification via telephone does not replace the need for the 
investigator to complete and sign the Serious Adverse Event  Report Form  within the de signated 
reporting time frames.  
• Contacts for SAE reporting can be found in the Investigator  Site Binder . 
9.5. Adverse Events of Special Interest  
Adverse events that are potentially immune -related will be assessed as AEs of special interest.  
Examples of these (including diagnostic algorithms to be followed) are provided in the American 
Society of Clinical Oncology and European Society for Medical Oncology  Clinical Practice 
Guideline s (Brahmer et al 2018 , Haanen  et al 2017 ).  Guidance for the management of irAEs are 
provided in Section  6.5.[ADDRESS_98079] interfered with the  effectiveness of a contraceptive medication or method .  When a 
pregnancy has been confirmed in a participant during maternal or paternal exposure to study 
drug, the following procedures should be followed in order to ensure safety:  
• The study drug must be discontinued immediately (female participants only ) 
• If the female participant is no longer pregnant and meets the treatment continuation 
criteria within 12 weeks  of the scheduled start of a cycle, study treatment may be 
resumed after approval has been rece ived from the sponsor medical monitor.  
• The investigator must complete and submit the Incyte Clinical Trial Pregnancy Form 
to the sponsor or its designee within 24 hours  of learning of the pregnancy.  
Data on fetal outcome are collected for regulatory report ing and drug safety evaluation .  
Follow -up should be conducted for each pregnancy to determine outcome, including spontaneous 
or voluntary termination, details of the birth, and the presence or absence of any birth defects, 
congenital abnormalities, or mat ernal and/or newborn complications, by [CONTACT_89210]-baby [CONTACT_765] .  Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported 
by [CONTACT_89211] .  Pregnancy follow -up information should be 
recorded on the same form and should include an assessment of the possible causal relationship 
to the sponsor 's study drug to any pregnancy outcome, as well as follow -up to the first well -baby 
[CONTACT_89212], whichever is later .  Refer to the Incyte 
Reference Guide for Completing the Clinical Trial Pregnancy Form.  
Any SAE occurring during pregnancy of a study participant must be recorded on the 
Serious Adverse Event  Report Form and submitted to the sponsor or designee.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, or ectopic pregnancy) are considered SAEs  (if occurring in the study participant) and 
must be reported as described in Section  9.4.  If an abnormal pregnancy outcome is reported in a 
study participant 's partner, the event should be reported to the sponsor on the Clinical Trial 
Pregnancy Form. 
9.8. Warnings and Precautions  
Special warnings or precautions for the study treatment , derived from safety information 
collected by [CONTACT_3552], are presented in in the INCMGA00012 IB .  Additional 
safety information coll ected between IB updates will be communicated in the form of 
Investigator Notifications .  Any important new safety information should be discussed with the 
participant during the study, as necessary .  If new significant risks  are identified, they will be 
added to the ICF.  
Incyte Corporation  Page [ADDRESS_98080] complaints associated with other 
study material will be reported directly to the respective manufacturer.  
The investigator or his/her designee is responsible for reporting a complete description of the 
product complaint via email or other written communication to the sponsor contact [CONTACT_89213] a s noted in the packaging information .  Any AE associated with a product 
complaint should be recorded as described in Section  9.3. 
If the investigato r is asked to return the product for investigation, he/she will return a copy of the 
product complaint communication with the product.  
9.10. Treatment of Overdose  
In the event of an overdose  of more than 25% , the investigator  should:  
• Contact [CONTACT_10990].  
• Document the quantity of the excess dose as well as the duration of the overdose in 
the eCRF.  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_89214].  
Incyte Corporation  Page 66 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  10. STATISTICS  
10.1. Sample Size Determination  
A pi[INVESTIGATOR_89160] -naive metastatic MCC shows a 
confirmed ORR of 39.7% with lower 9 5% CI of 30.7% (D'Angelo  et al 2019 ).  A pi[INVESTIGATOR_89161] 56% with lower 95% CI of 35% 
(Nghiem et al 2016 , Nghiem et al 2019 ). 
Based on the results from studies of avelumab and pembrolizumab, it is reasonable to target a 
response rate of approximately  48%.  Approximately 60  chemotherapy -naive participants  will be 
enrolled  for the primary analysis .  Based on a target ORR of 48% and  a sample size of 
approximately 60 , this  study has over 80% power to exclude the lower 95% confidence limit of 
30% with α = 0.025 (1 -sided) in the chemotherapy -naive population . 
Approximately 100 chemotherapy -naive participants will be enrolled for the final analysis.  This 
sample size ensures that half of the 95% CI will be approximately 10% for an ORR ranging from 
40% to 60%.   This sample size also ensures 99% power to detect any AE with an underlying 
event rate as low as  0.5%.  
Note:  Participants who had received prior chemotherapy for MCC were enrolled up to 
Amendment 4.  
10.2. Populations for Analysis  
Table  25: Populations for Analysis  
Populatio n Description  
FAS The FAS includ es all participants enrolled in the study who received at least [ADDRESS_98081] 60 chemotherapy -naive participants .  The 
FAS will be used for the summary of demographics, baseline characteristics, 
participant disposition , and efficacy .  Note:   this analysis population will be used in 
the interim CSR.  
Efficacy 
evaluable 
population  The efficacy evaluable population includes al l participants  from the FAS with a 
centrally confirmed diagnosis of MCC who are evaluable according to RECIST v1.[ADDRESS_98082] 1  postdose PK 
sample.  
10.3. Level of Significance  
There is no formal hypothesis testing in this study.  Response rate as well as the associated 
95% CI will be provided.  
Incyte Corporation  Page [ADDRESS_98083] 6 months after confirmed response.  If the study meets the predefined 
efficacy threshold at the primary analysis  (see Section  10.1), the final analysis will occur after all 
[ADDRESS_98084] been enrolled and followed for survival for a minimum of 2 years.  
10.4.1.  Primary Analysis  
[IP_ADDRESS].  Overall Response Rate  
The primary endpoint of the study is ORR  in the chemotherapy -naive population , defined  as the 
proportion of participants with an objective response ( CR or PR ), according to RECIST v1.1 
(Eisenhauer et al 2009 ) as determined by [CONTACT_89215].  The primary analysis of ORR will be based on 
the chemotherapy -naive subs et of the FAS, as defined in Table  25.  Overall response rate and its 
exact 95% CI will be presented.   The a nalysis will be assessed  using the efficacy evaluable 
population as a sensitivity analysis.   The ORR will be assessed again at the final analysis using 
the safety evaluable population.  
[IP_ADDRESS].  Handling of Missing Data in Primary Analysis  
The efficacy evaluable population must have measurable diseas e at baseline per RECIST v1.1.  
Participant s with subsequent missing assessments that prevent the evaluation of the primary 
endpoint will be considered as nonresponders.  No data imputation will be applied.   
A response assessment  of CR or PR reported before any additional anticancer therapy will be 
considered as a response in the calculation of ORR irrespective of the number of miss ed 
assessments before response.  
10.4.2.  Secondary Analysis  
[IP_ADDRESS].  Duration of Response  
Duration of response is defined as the time from first documented objective response (CR or PR) 
to the time of first documented disease progression according to RECIST v1.[ADDRESS_98085] imated median along 
with 95% CI  will be reported.   Duration of response  will be analyzed usin g the FAS at the 
primary analysis and may be assessed using the safety evaluable populatio n at the final analysis.  
[IP_ADDRESS].  Disease Control Rate  
Disease control rate is  defined as the proportion of participants with either an objective response 
(CR and PR) or SD  lasting at least [ADDRESS_98086] v1.1 .  Disease control rate  
Incyte Corporation  Page 68 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  will be assessed for chemotherapy -naive particip ants using the FAS at the primary analysis and 
may be assessed using the safety evalua ble population at the final analysis . 
[IP_ADDRESS].  Progression -Free Survival  
Progression -free survival, defined as the time from first dose of study treatment to the date of the 
first d ocument ed progression per RECIST v 1.1 by [CONTACT_89216].  
Progression -free survival data will be analyzed by [CONTACT_8761] -Meier method, including estimated 
median with 95% CI, and Kaplan -Meier estimated probabilities at several timepoints.   If an event 
is not observed, PFS will be censored at the last adequat e tumor assessment before  cutoff or new 
anticancer  therapy.   Progression -free survival  will be assessed for chemotherapy -naive 
participants  using the FAS at the primary analysis and may be assessed using the safety  
evaluable population at the final analysis . 
[IP_ADDRESS].  Overall Survival  
Overall survival is defined as the time from first dose of study treatment to the date of death due 
to any cause.  Kaplan -Meier estimate of OS will be provided, including median and its 95% CI.   
Participants still alive at time of analysis will be censored at the date last confirmed to be alive .  
Kaplan -Meier curves, m edians, and 95% CIs of the medians will be presented.   Overall survival 
will be assessed for chem otherapy -naive participants  using the FAS at the primary analysis and 
may be assessed using safety evaluable population at the final analysis . 
10.4.3.  Safety Analyses  
The clinical safety data (eg, vital signs, ECGs, routine laboratory tests, physical examinations,  
and AEs) will be summarized using descriptive statistics (eg, mean, frequency) using the safety 
evaluable population.   The safety analysis will be performed separately for chemotherapy -naive 
participants and the full study population.  
Summary tables may b e replaced with listings when appropriate.  For instance, an AE frequency 
table may be replaced with a listing if it only contains a few unique preferred terms reported on 
relatively few participants.  
[IP_ADDRESS].  Adverse Events  
Safety analyses will be conducted for the safety  evaluable  population.  Adverse events will be 
coded according to  MedDRA, and treatment -emergent AEs (ie, AEs reported for the first time or 
worsening of a pre -existing event after first dose of study treatment) will be tabulated by 
[CONTACT_89217] m and system organ class for all events, related events, and events of Grade 3 or 
higher .   
[IP_ADDRESS].  Adverse Events of Special Interest  
Adverse events of special interest will include irAEs . 
[IP_ADDRESS].  Clinical Laboratory Tests  
The clinical laboratory data will be analyzed us ing summary statistics.  In addition, distributions 
of key laboratory parameters may be plotted over time; these values will also be classified into 
CTCAE toxicity grades, and tabulated.   
Incyte Corporation  Page [ADDRESS_98087] values outside the normal range will be assessed fo r severity based on the normal 
ranges for the clinical reference laboratory.  The incidence of abnormal laboratory values and 
shift tables relative to baseline will be tabulated.   The following summaries will be produced for 
the laboratory data:  
• Number an d percentage of participant s with worst postbaseline CTCAE grade 
(regardless of baseline value).  Each participant  will be counted only for the wor st 
grade observed postbaseline.  
• Shift tables from baseline to the worst postb aseline value using CTCAE grade.  
• For laboratory parameters where CTCAE grades are not defined, shift tables to the 
worst postbaseline value using the low/normal/high classifications based on 
laboratory reference ranges.  
[IP_ADDRESS].  Vital Signs  
Descriptive statistics and mean change from baseline wil l be determined for vital signs (blood 
pressure, O2 saturation, pulse, respi[INVESTIGATOR_697], and body temperature) at each assessment time.  
Vital sign results will be reviewed for clinically notable abnormalities, and participant s 
exhibiting clinically notable vital sign abnormalities will be listed.  
[IP_ADDRESS].  Electrocardiograms  
Descriptive statistics and mean change from baseline will be determined for each ECG parameter 
at each assessment time.  Electrocardiogram results will be reviewed for clinically notable 
abnormalities according to predefined criteria as described in the Statistical Analysis Plan.  
[IP_ADDRESS].  Dose Intensity  
Measures of exposure (eg, days of exposure, dose intensity) of study drug will be summarized by 
[CONTACT_63408].  
10.4.4.  Pharmacokinetics  
If the re is a sufficient amount of serum concentration data from this study, the data will be 
analyzed by [CONTACT_89218] (eg, NONMEM).  
Otherwise, the data will be pooled with data from other studies for a population PK  analysis.  
10.4.5.  Exploratory Analys es 
 
 
 
 
 

Incyte Corporation  Page 70 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL   
 
 
 
  
 
 
 
 
 
[IP_ADDRESS].  Efficacy Endpoints for Full Study Population  
Efficacy will be determined for the full  study population, including participants who are 
chemotherapy -naive and those participants who received prior chemotherapy who enrolled 
before Amendment 5.  
The ORR in the full study population, comprised of chemotherapy -naive and chemotherapy -
refractory p articipants, will be evaluated as an exploratory endpoint.  The ORR and its exact 
95% CI will be presented.  The ORR in chemotherapy -refractory participants will be provided as 
a subgroup analysis.  The ORR in the full study population will be analyzed usi ng the FAS at the 
primary analysis . 
Duration of response, DCR, PFS, and OS will be analyzed using the methods described in  
Section s [IP_ADDRESS] , [IP_ADDRESS] , [IP_ADDRESS] , and [IP_ADDRESS] .  These endpoints will be assessed separately 
for chemotherapy -naive par ticipants and the full study population.  
10.5. Futility Analysis  
An analysis is planned after approximately 20 chemotherapy -naive participants are assessable for 
response.   The primary intent of this analysis is to minimize unnecessary exposure of participants 
to INCMGA00012 in the event of futility.   The futility analysis will be based on conditional 
power /probability of success t o achieve the primary endpoint of target ORR.  Enrollment will 
continue while the analysis is being conducted.  This futility analysis will be reviewed by [CONTACT_89219].  The process by [CONTACT_89220].  This 
futility analysis will be desc ribed in greater detail in the Statistical Analysis Plan. 
As of Protocol  Amendment 6, the DMC has reviewed the data for the interim analysis.  The 
preliminary efficacy based on the ORR assessed by [CONTACT_89180] , and the 
DMC recommende d the study to proceed as planned.  

Incyte Corporation  Page 71 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  11. SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  
11.1. Investigator Responsibilities  
• The Protocol , Protocol amendments, ICF, IB, and other relevant documents 
(eg, advertisements) must be submitted to an IRB/IEC by [CONTACT_89221]/IEC  before the study is initiated . 
• The investigator is responsible for ensuring that the safety reports provided by [CONTACT_89222] , the 
polic ies and procedures established by [CONTACT_1201]/IEC , and institutional requirements . 
• Any amendments to the Protocol will require health authorities or regulatory agencies 
and IRB/IEC approval before implementation of changes made to the study design, 
except for changes necessary to eliminate an immediate hazard to study participants.  
• The investigator will be responsible for the following:  
− Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requi rements, policies, and procedures 
established by [CONTACT_1201]/IEC . 
− Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures . 
− Providing oversight of the conduct of the study at the site and adherence to GCP , 
IRB/IEC requirements, institutional requirements, and applicable laws and 
country -specific regulations . 
• Adhering to the Protocol as described in this document and agreeing that changes to 
the Protocol procedures, with the exception of medical emergencies, must be 
discussed and approved, first, by [CONTACT_89223], second, by [CONTACT_5040]/IEC.  Each investigator is responsible for enrolling participants who have met 
the specified eligibility criteria.  
• Retaining records in accordance with all local, nationa l, and regulatory laws, but for a 
minimum period of at least [ADDRESS_98088] article for 
investigation to ensure the availability of study documentation should it become 
necessary for the sponsor or a regulatory authority to review.  
− The investigator must not destroy any records associated with the study wi thout 
receiving approval from the sponsor.  The investigator must notify the sponsor or 
its designee in the event of accidental loss or destruction of any study records.  If 
the investigator leaves the institution where the study was conducted, the sponsor  
or its designee must be contact[CONTACT_89224].  
− All eCRF data entered by [CONTACT_779] (including audit trail), as well as computer 
hardware and software (for accessing the data), will be maintained or made 
available at the sit e in compliance with applicable record retention regulations.  
The sponsor will retain the original eCRF data and audit trail.  
Incyte Corporation  Page 72 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  11.2. Data Management  
Data management will be performed in a validated EDC system.  Data from external vendors 
may also be integrated into the clinical database.  The investigator will be provided with access 
to an EDC system so that an eCRF can be completed for each participant.  
The site will be provided eCRF completion guidelines for in structions on data entry in the eCRF.  
The study monitor will reference the Monitoring Plan in order to ensure that each issue identified 
is appropriately documented, reported, and resolved in a timely manner in accordance with the 
plan's requirements.  
The sponsor (or designee) will be responsible for:  
• The data management of this study including quality checking of the data . 
• Ensuring that s tudy monitors perform ongoing source data verification to confirm that 
data entered into the eCRF by [CONTACT_42535], complete, and 
verifiable from source documents; that the safety and rights of participants are being 
protected; and that the study is being conducted in accordance with the currently 
approved protocol and any other study agreements, I CH GCP, and all applicable 
regulatory requirements . 
The investigator will be responsible for:  
• Ensuring participant data relating to the study is recorded in the eCRF unless 
transmitted to the sponsor or designee electronically (eg, laboratory data, diary d ata) 
or as otherwise specified in the Protocol.  The investigator is responsible for verifying 
that data entries are accurate and correct by [CONTACT_21496].  
• Maintaining accurate documentation (source data) that supports the i nformation 
entered in the eCRF.  
− Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected.  Source documents are filed at the 
investigator 's site.  
− Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies 
must be explained.  The investigator may need to request previous medical 
records or transfer records, depending on the study.  Also, current medical records 
must be available.  
• Permitting study -related monitoring, sponsor audits, IRB/IEC review, and regulatory 
inspections by [CONTACT_89225].  
− Monitoring:  Qualified representatives  of the sponsor or its designee, study 
monitors, will monitor the study according to a predetermined plan.  The 
investigator must allow the study monitors to review any study materials and 
participant records at each monitoring visit.  
Incyte Corporation  Page 73 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  − Auditing:  Qualified representatives of the sponsor or its designee may audit the 
clinical study site and study data to evaluate compliance with the Protocol, 
applicable local clinical study regulations, and overall study conduct.  The 
investigator must allow the auditors to r eview original source records and study 
documentation for all participants.  
− Regulatory inspection:  Regulatory authorities may conduct an inspection of the 
study and the site at any time during the development of an investigational 
product.  The investigat or and staff are expected to cooperate with the inspectors 
and allow access to all source documents supporting the eCRFs and other 
study -related documents.  The investigator must immediately notify the sponsor 
when contact[CONTACT_89226].  
11.3. Data Privacy and Confidentiality  of Study Records  
The investigator and the sponsor or its designee must adhere to applicable data privacy laws and 
regulations .  The investigator and the sponsor or its designee are  responsible for ensuring that 
sensitive information is handled in accordance with local requirements ( including but not limited 
to HIPAA  and GDPR ) as applicable .  Appropriate consent for collection, use , and disclosure 
and/or transfer (if applicable) of personal information  must be obtained  in accordance with local 
data protection laws . 
Participant names will not be supplied to the sponsor or its designee .  Only the participant 
number will be recorded in the eCRF; if the participant 's name [CONTACT_89235] o ther document 
(eg, laboratory report), it must be obliterated on the copy of the document to be supplied to the 
sponsor or its designee .  Study findings stored on a computer will be stored in accordance with 
appropriate technical and organizational measure s as required by [CONTACT_89227] . 
Records and documents, including signed ICFs, pertaining to the conduct of this study must be 
retained by [CONTACT_1732] 10 years after study completion unless local regulations or 
institutional policies r equire otherwise .  No records may be destroyed during the retention period 
without the written approval of the sponsor.  No records may be transferred to another location 
or party without written notification to the sponsor.  
11.4. Financial Disclosure  
Before study initiation, all clinical investigators participating in clinical studies participant  to 
FDA Regulation Title 21 CFR Part 54 – Financial Disclosure by [CONTACT_6230] 
(ie, "covered studies ") are required to submit a completed Clinical In vestigator Financial 
Disclosure form that sufficiently details any financial interests and arrangements that apply .  For 
the purpose of this regulation, "clinical investigator " is defined as any investigator or 
subinvestigator who is directly involved in t he treatment or evaluation of research participants, 
including the spouse and each dependent child of the clinical investigator or subinvestigator .  
These requirements apply to both US and foreign clinical investigators conducting covered 
clinical studies.  
Any new clinical investigators added to the covered clinical study during its conduct must also 
submit a completed Investigator Financial Disclosure Form .  During a covered clinical study, 
Incyte Corporation  Page [ADDRESS_98089] udy. 
11.5. Publication Policy  
By [CONTACT_89228], the investigator and his /her institution agree that the results of the 
study may be used by [CONTACT_456], Incyte Corporation, for the purposes of national and 
international registration, publication, an d information for medical and pharmaceutical 
professionals.  Study results will be published in accordance with applicable local and national 
regulations.  If necessary, the authorities will be notified of the investigator 's name, address, 
qualifications, and extent of involvement.  The terms regarding the publication of study results 
are contained in the agreement signed with the sponsor or its designee.  A signed agreement will 
be retained by [CONTACT_3552].  
The results of this study may be published or presented at scientific meetings .  If this is foreseen, 
the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission .  
This allows the sponsor to protect proprietary information and to provide comments . 
The s ponsor will comply with the requirements for publication of study results .  In accordance 
with standard editorial and ethical practice, the sponsor will generally support publication of 
multicenter studies only in their entirety and not as individual site data.  In this case, a 
coordinating investigator [INVESTIGATOR_12992].  
Authorship will be determined in line with International Committee of Medical Journal Editors 
authorship requirements.  
11.6. Study and Site Closure  
The sponsor designee rese rves the right to close the study site or terminate the study at any time 
for any reason at the sole discretion of the sponsor .  Study sites will be closed upon study 
completion .  A study site is considered closed when all required documents and study supp lies 
have been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_11004]:  
• Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor 's procedures, or GCP guid elines . 
• Inadequate recruitment of participants by [CONTACT_093] . 
• Discontinuation of further study treatment  development . 
Incyte Corporation  Page 75 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  12. REFERENCES  
Allen PJ, Browne WB, Jaques DP, Brennan MF, Busam K, Coit DG . Merkel cell carcinoma: 
Prognosis and treatment of pa tients of a single institution.  J Clin Onc ol 2005 ;23:2300 -2309. 
American Society of Clinical Oncology. COVID -19 Vaccine & Patients with Cancer. 2021. 
Accessed 01  December 2021. https://www.asco.org/covid -resources/vaccines -patients -cancer  
Bai S, Jorga K, Xin Y, et al. A guide to rational dosing of monoclonal antibodies. Clin 
Pharmacokinet 2012;51:119 -135. 
Becker JC. Merkel ce ll carcinoma. Ann Oncol 2010 ;21(suppl 7):vii81 –vii85.  
Becker JC, Stang A, DeCaprio JA, et al. Merkel cell carcinoma.  Na t Rev Dis Primers 
2017 ;3:[ZIP_CODE].  
Berton D, Pautier P, Lorusso D, et al. Retifanlimab (INCMGA00012) in patients with advanced 
solid tumors: top-line results for the recurrent MSI -high or dMMR endometrial cancer cohort of 
POD1UM -101. Presented at: SITC 36th A nnual Meeting; November 10 -14, 2021; 
Washington,  DC. 
Bhatia S, Afanasiev O, Nghiem P. Immunobiology of Merkel cell carcinoma: implications for 
immunotherapy of a polyomavirus -associated cancer. Curr Oncol Rep 2011;13:488 -497. 
Brahmer J R, Lacchetti C, Schne ider B, et al. Management of immune -related adverse events in 
patients treated with i mmune  checkpoint inhibitor therapy: American Society of Clinical 
Oncology Clinical Practice Guideline.  J Clin Oncol  2018 ;36:1714 -1768.  
Cassler NM, Merrill D, Bichakjian CK, Brownell I. Merkel cell carcinoma therapeutic update. 
Curr Treat Options Oncol 2016 ;17:36. 
Clinical Trial Facilitation Group. Recommendations related to contraception and pregnancy 
testing in clinical trials. 2014. http://www.hma.eu/filead min/dateien/  
Human_Medicines/01 -About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_  
Contraception.pdf. Accessed June 7, 2018 . 
Curigliano G, Banerjee S, Cervantes A, et al. Managing cancer patients during the COVID -19 
pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol 2020;31:1320 -1335.  
D'Angelo S , Lebbe C, Mortier L, et al. First -line avelumab treatment in patients with metastatic 
Merkel cell carcinoma: primary analysis after ≥ 15 months of follow -up from JAVELIN Merkel 
200, a registrational phase 2 trial. J Immunother Cancer  2019;7(suppl 1):282  [abstr  P362 ]. 
D'Angelo SP, Russell J,  Lebbé C, et al . Efficacy and safety of first -line avelumab treatment in 
patients with Stage IV metastatic Merkel cell carcinoma : a preplanned interim analysis of a 
clinical trial  [published online ahead of print March 22, 2018] . JAMA Oncol 
doi:10.1001/jamaoncol.2018.0077 . 
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: 
revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:[ADDRESS_98090] COVID -19 in 
patients with cancer. EMSO Statements (2021).  Accessed 01 December 2021.  
https://www.esmo.org/covid -19-and-cancer/covid -19-vaccination  
Incyte Corporation  Page 76 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Freshwater  T, Kondic A, Ahamadi M , et al. Evaluation of dosing strategy for pembrolizumab for 
oncology indications. J Immunother Cancer  2017;5:43 . 
Grignani G, Rutkowski P, Lebbe C, et al. A phase 2 study of retifanlimab in patients with 
advanced or metastatic merkel cell carcinoma (POD1UM -201). Presented at: SITC 36th Annual 
Meeting; November 10 -14, 2021; Washington, DC. Poster 545.  
Haanen JBAG, Carbonnel F, Robert C, et al.  Management of toxicities from immunotherapy: 
ESMO Clinical Practice Guidelines for diagnosis, treatment and follow -up. Ann Oncol 
2017;28:i v119-iv142. 
Horn L, Whisenant J, Torri V, et al. Thoracic Cancers Internat ional COVID -19 Collaboration 
(TERAVOLT): impact of type of cancer therapy and COVID therapy on survival. J Clin Oncol 
2020;39(suppl 18):Abstract LBA111.  
Hughes  MP, Hardee ME, Cornelius LA, Hutchins LF, Becker JC, Gao L . Merkel cell carcinoma: 
epi[INVESTIGATOR_623],  target , and therapy. Curr Dermatol Rep 2014 ;3:46-53. 
INCMGA [ZIP_CODE] Investigator 's Brochure. Wilmington, DE: Incyte Corporation.  
Kaufman HL, Russell J, Hamid O , et al. Avelumab in patient with chemotherapy -refractory 
metastatic Merkel cell carcinoma: a multi center, single -group, open -label, phase 2 trail. Lancet 
Oncol 2016;17:1374 -1385 . 
Kaufman HL, Hunger M, Hennessy M, Schlichting M, Bharmal M. Nonprogression with 
avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma . 
Future Onc 2018 ;14:255 -266. 
Lakhani N, Mehnert JM, Rasco D, et al. A phase 1 study of the safety, tolerability, and 
pharmacokinetics (PK) of MGA012 (anti -PD-1 antibody) in patients with advanced solid tumors. 
Poster presented at : 32nd Congress of the Society for Immunotherapy of Cancer; 
November  8-12, 2017; National Harbor, MD. Abstract P249.  
Lebbe C, Becker JC, Grob JJ, et al. Diagnosis and treatment of  Merkel cell carcinoma. European  
consensus -based interdisciplinary guideline. Eur J Cancer 2015 ;51:2396-2403. 
Lee LY, Cazier JB, Angelis V, et al. COVID -19 mortality in patients with cancer on 
chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 
2020;395:1919 -1926.  
Maio M, Schenker M, Medioni J, et al. Phase 2 study of retifanl imab (INCMGA00012) in 
patients (pts) with selected solid tumors (POD1UM -203).  J Clin Oncol 
2021; 39(suppl ):Abstract  2571 . 
Malek AE, Cornejo PP, Daoud N, and Alam M. The mRNA COVID -19 vaccine in patients with 
cancer receiving checkpoint inhibitor therapy: wh at we know and what we don’t  [published 
online ahead of print November 8, 2021]. Immunotherapy. doi:10.2217/imt -2021 -0235.  
Mandala M, Lorigan P, DeLuca M, et al. SARS -CoV -2 infection and adverse events in patients 
with cancer receiving immune checkpoint inhibitors: an observational prospective study. 
J Immunother Cancer 2021 ;9:e001694.  
Incyte Corporation  Page [ADDRESS_98091] -in-human phase 1 study of INCMGA00012 i n 
patients with advanced solid tumors: interim results of the cohort expansion phase .  
J Immunother Cancer 2018;6( suppl 1):357 [abstr P669 ]. 
Mehnert J, Paz-Ares L, Pi[INVESTIGATOR_89162] J, et al. A phase 1 study of INCMGA00012, a PD -1 inhibitor, in 
patients with advanced  solid tumors: preliminary results for patients with advanced cervical 
cancer (POD1UM -101). J Immunother Cancer 2019;7(suppl 1):215 [abstr P394].  
National Comprehensive Cancer Network. National Comprehensive Cancer Network Clinical 
Practice Guidelines in O ncology: Management of Immunotherapy -Related Toxicities 
Version  3.2021. 2021 b. 
National Comprehensive Cancer Network.  National Comprehensive Cancer Network Clinical 
Practice Guidelines in Oncology: Merkel Cell Carcinoma Version 1.2017. 2017.  
National Compr ehensive Cancer Network. National Comprehensive Cancer Network Clinical 
Practice Guidelines in Oncology: Merkel Cell Carcinoma Versio n 2.2019. 2019.  
National Comprehensive Cancer Network. National Comprehensive Cancer Network  COVID -19 
vaccination guide for  people with cancer . 2021 a. 
Nghiem PT, Bhatia S, Lipson EJ, et al. PD -1 blockade with pembrolizumab in advanced 
Merkel -cell carcinoma. N Engl J Med 2016;374:[ADDRESS_98092] -line therapy . J Clin 
Oncol 2019;37:693 -702. 
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern 
Cooperative Oncology Group. Am J Clin Oncol 1982;5 :649-655. 
Passaro A, Bestvina C, Velez Velez M, Garassino MC, Garon E, Peters S. Severity of 
COVID -19 in patients with lung cancer: evidence and challenges. J Immunother Cancer 
2021;9:e002266.  
Rao S, Capdevila J, Gilbert D, et al. POD1UM -202: phase II  study of retifanlimab in patients 
(pts) with squamous carcinoma of the anal canal (SCAC) who progressed following 
platinum -based chemotherapy . Ann Oncol 2020;31(suppl 4);S1170 -S1171 [abstr LBA42] .  
Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and safety  outcomes in patients with 
advanced melanoma who discontinued treatment with nivolumab and ipi[INVESTIGATOR_89163]: a pooled analysis of randomized phase II and III trials. J Clin Oncol 
2017 ;35:3807 -3814. 
 
Sharafeldin N, Bates B, Song Q, et al. Outcomes of Covid -19 in patients with cancer: report from 
the National Covid Cohort Collaborat ive (N3C). J Clin Oncol 2021;39:2232 -2246.  
Voog E, Biron P, Martin JP, Blay JY. Chemotherapy for patient with locally advanced or 
metastatic Merkel cell carcinoma.  Cancer 1999 ;85:2589 -95. 

Incyte Corporation  Page 78 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus bod y size -based dosing 
of monoclonal antibodies in adult clinical trials. J Clin Pharmacol 2009;49:1012 -1024.  
Incyte Corporation  Page 79 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  APPENDIX  A. INFORMATION REGARDIN G EFFECTIVENESS OF 
CONTRACEPTIVE METHOD S 
For male participants in the study:  
Male participants should use a condom during treatm ent and through [ADDRESS_98093] had a vasectomy qualify as having met the 
requirement for a highly effective birth control method.  
For female participants in the study:  
The following methods that can achieve a failure rate of less than 1% per year when used consistently 
and correctly are considered as highly effective birth control methods:  
• Combined (estrogen and progestogen containing) hormona l contraception associated with 
inhibition of ovulationa 
− oral 
− intravaginal  
− transdermal  
• Progestogen -only hormonal contraception associated with inhibition of ovulationa 
− oral 
− injectable  
− implantableb 
• Intrauterine deviceb 
• Intrauterine hormone -releasing systemb 
• Bilateral tubal occlusionb 
• Vasectomized partnerbc 
• Sexual abstinenced 
Acceptable birth control methods that result in a failure rate of more than 1% per year include:  
• Progestogen -only oral hormonal contraception, where inhibition of ovulation is not the primary 
mode of action  
• Male or female condom with or without spermicidee 
• Cap, diaphragm, or sponge with spermicidee 
• Tubal ligation  
a Hormonal contraception may be susceptible to interaction with the investigational medicinal product, which may 
reduce the efficacy of the contraception method.  
b Contraception methods that in the context of this guidance are considered to have low user dependency.  
c Vasectomized partner is a highly effective method of avoiding pregnancy provided that partner is the sole sexual 
partner of the woman of childbearing potential study participant and that the vasectomized partner has received 
medical assessment of the surgical success.  
d In the context of this guidance, sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated with the study treatments.  The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the 
preferred and usual lifestyle of the participant.  
e A combination of male condom with either cap,  diaphragm, or sponge with spermicide (double barrier methods) 
are also considered acceptable, but not highly effective, birth control methods.  
Source:  Clinical Trial Facilitation Group [ADDRESS_98094] v1.1 are provided below.  For full details, refer to  
Eisenhauer  et al 2009 . 
Evaluation of Target Lesions  
CR Disappearance of all target lesions .  Any pathological lymph nodes (whether target or nontarget must 
have reduction in short axis to <  10 mm).  
PR At least a 30% decrease in the sum of diameters  of target lesions, taking as reference the baseline sum 
diameters . 
PD At least a 20% increase in  the sum of diameters  of target lesions, taking as reference the smallest sum on 
study (this includes the baseline sum if that is the smallest on study) , and the sum must also demonstrate 
an absolute increase of at least [ADDRESS_98095] sum diameters  while on study . 
CR = complete response; PD = progressive disease; PR = partial response; SD = stable  disease.  
Evaluation of Non target Lesions  
CR Disappearance of all nontarget lesions and normalization of tumor marker level .  All 
lymph  nodes must be nonpathological  in size (<  10 mm short axis).  
Non-CR/ 
Non-PD Persistence of 1 or more nontarget lesion(s) and /or maintenance of tumor marker level 
above the normal limits . 
PD Unequivocal progression of existing nontarget lesion s.a 
CR = complete response; PD = progressive disease; SD = st able disease.  
a Although a clear progression of "nontarget " lesions only is exceptional, in such circumstances, the opi[INVESTIGATOR_89164], and the progression status sh ould be confirmed later on by [CONTACT_463] (or study chair).  
Evaluation of New  Lesions  
PD The appearance of new malignant lesions denotes disease progression.  The finding of a 
new lesions should be unequivocal.  
Incyte Corporation  Page [ADDRESS_98096] Overall Response  
• The best overall response is the best response recorded from the start of the treatment 
until disease progression/recurrence (taking as reference for PD the smallest 
measurements recorded since the treatment started).  In general, the participant 's best 
response assignment will depend on the achievement of both measurement and 
confirmation criteria.  
Target lesions  Nontarget Lesions  New Lesions  Overall Response  
CR CR No CR 
CR Non-CR/Non -PD No PR 
CR Not evaluated  No PR 
PR Non-PD or N ot all evaluated  No PR 
SD Non-PD or N ot all evaluated  No SD 
Not all evaluated  Non-PD No NE 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
CR = complete response; PD = progressive disease; PR = partial response; NE = not evaluable; SD = stable disease.  
• Participants with a global deterioration of health status requiring discontinuation of 
treatment without objective evidence of disease progression at that time should be 
classified as having "clinical progression ."  Every effort should be made to document 
the objective progression even after discontinuation of treatment.  
• In some circumstances , it may be difficult to distinguish residual disease from normal 
tissue.  When the evaluation of CR depends on this determination, it is recommended 
that the residual lesion be investigated (fine needle aspi[INVESTIGATOR_337]/biopsy) to confirm the CR 
status.  
Source:  Eisenhauer et al [ADDRESS_98097] of clinical trials.   In 
line with regulatory guidance regarding clinical study execution during the pandemic, the  
sponsor has issued the following protocol cons iderations to ensure participant safety is  
maintained and adequate benefit/risk analyses are applied relative to participation in the study,  
the completion of study procedures, and objectives.  
Recognizing the dynamic nature and flexibility required to mana ge the impact of the pandemic 
on this clinical study, additional details will be incorporated into respective study manuals and 
site-specific monitoring plans as applicable, with institutional requirements as warranted, and 
communicated and discussed with investigative sites as needed.  Relevant test results will be 
documented in the eCRF, and applicable changes to the ICF will be made and monitored.  
SARS -CoV2 Infection and Participation in the Study  
Benefit/risk assessment in the context of the COVID -[ADDRESS_98098] either related to going to a  
healthcare facility or as a result of study -related activities.  It is at the investigator's discretion to  
balance the risk/benefit while considering the participant's safety, existing comorbidities, and  
current malignancy.  In addition, country -specific r equirements are to be followed with regard to  
COVID -19 testing.  
Study Site Visits  
If local travel restrictions, isolation requirements, or the investigator's benefit/risk assessment  
determines it to be unsafe for participants to attend study visits at the investigational site, the site  
staff may elect to pursue the following:  
• In order to minimize participant risk, some study procedures may be conducted via 
telemedicine modalities (phone or video), where appropriate, or as per institutional 
guidelines during  the COVID -[ADDRESS_98099] be completed.  On-site visits should be conducted 
whenever feasible and are required for administration of study  treatment .  The 
participant may also be asked to underg o additional safety laboratory  assessments.  
• During COVID -19 restrictions only,  scans for disease assessments may be delayed 
by [CONTACT_33018] 7 days from the time allowed in the protocol ( see Table  3).  If 
necessary, scans may be done at a different hospi[INVESTIGATOR_89165].  It is the investigator 's responsibility to confirm that the 
exter nal facility meets these requirements before any scans are performed at that 
location.  
Study Treatment Administration:  
• Treatment delays of > 12 weeks for logistical reasons (eg, travel restrictions due to  
COVID -19) may be acceptable but must be discu ssed w ith the medical monitor.  
Incyte Corporation  Page 86 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Study Treatment Management in the Event of SARS -CoV -2 Infection  
If a participant develops a SARS -CoV2 infection, the event should be reported as an AE or SAE 
(if it meets the SAE definition requirements according to  Section  9.2) and appropriate medical  
intervention provided.   COVID -19 testing should follow country -specific requirements 
depending on the  extent of COVID -19 pandemic, local institutional guidance, or investigator's 
clinical judgment.   For participants who are diagnosed with COVID -19 during the study 
(positive COVID -[ADDRESS_98100])  or presumed affected by [CONTACT_7544] -CoV -2 infection (test pending/clinical 
suspi[INVESTIGATOR_2798]), study t reatment  should be delayed until COVID -[ADDRESS_98101] normalization and clinical 
recovery.  Safety monitoring following COVID -19 infection should be implemented as per 
institutional  guidance or clinical judgment (eg, coagulation factors).   Concomitant medication 
administered  for treatment of SARS -CoV -2 infection should be carefully considered for potential 
drug-drug interactions and medications should be recorded in the eCRFs.  
COVID -19 Vaccination During Participation in the Study  
Participa nts may receive the COVID -19 vaccine as lo ng as it is not a live vaccine.  
• It is recommended that COVID vaccine is not administered on the day  of 
INCMGA00012 infusion.  Administration of study treatment may be delayed by 
3 days to ensure vaccination is comp leted and acute AEs (if any) are managed.  
• The COVID -[ADDRESS_98102] be entered in the E DC as a concomitant medication.  
• Any AEs resulting from the vaccination and medications for treating the AEs must be 
entered in eCRFs.  
Clinical Study Monitoring  
Study  monitoring visits could be postponed; however, the site monitor and sponsor will continue  
to employ off -site monitoring practices such as routine communication methods (eg, phone calls,  
emails, video visits , remote visits with source data monitoring where  allowed ) with the sites to 
get information on study progress, participant status, and  information on issue resolution. The 
study monitor may remotely review data entered into the  EDC for accuracy and completeness if 
allowed by [CONTACT_89229] , investigational  site, and/or in compliance with local 
authorities.  
Reimbursement of Additional Expenses  
The sponsor will reimburse for any extraordinary expenses, keepi[INVESTIGATOR_89166] (eg, travel expenses for the local laboratory  visit[s], the costs of local [proximate] 
laboratory tests).  
Incyte Corporation  Page 87 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  APPENDIX  E. PROTOCOL AMENDMENT S UMMARY OF CHANGES  
Document  Date  
Amendment (Version) 1 : 27 JUN 2018  
Amendment (Version) 2:  [ADDRESS_98103] 2018  
Amendment (Version) 3 : 05 DEC 2018  
Amendment (Version) 4:  16 AUG 2019  
Amendment (Version) 5 : 09 APR 2020  
Amendment (Version) 6:  [ADDRESS_98104] 2020  
Amendment (Version) 7:  16 DEC  2021  
Amendment 7 ( 16 DEC 2021)  
Overall Rationale for the Amendment:   The primary purpose of this amendment is to update 
irAE management guidelines to reflect updated published guidance  and to provide guidance on 
the management of participants during the COVID -19 pandemic .  Additional changes are 
summarized below.  
1. Section 2.2, Study Rationale  
Description of change:   Background information on safety and efficacy of 
INCMGA00012 was updated to reflect more recent data.  
Rationale for change:   To provide investigators with the most recent safety and efficacy 
data for their knowledge.  
2. Section 2.3.1, Benefit/Risk Assessmen t During the COVID -19 Pandemic; 
Section  8.3.6, Laboratory Assessments (Table 22 :  Required Laboratory Analytes ); 
Appendix D, COVID -19 Pandemic Mitigation Strategies and Instructions  
Description of change: Information regarding the COVID -19 pandemic includi ng a 
risk/benefit assessment and instructions for changes to protocol -required procedures have 
been added to the protocol.  
Rationale for change:  To provide additional information regarding COVID -19. 
3. Section 6.5.1, Management of Suspected Infusion Reaction s (Table 8 :  Guidelines for 
Management of Suspected Infusion Reactions ) 
Description of change:   Minor updates  to guidance for infusion reactions . 
Rationale for change:   Updates reflect evolving guidance in published 
recommendations . 
Incyte Corporation  Page 88 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  4. Section 6.5.2, Procedures for Participants Exhibiting Immune -Related Adverse 
Events; Section 9.5, Adverse Events of Special Interest  
Description of change :  Updated and/or added irAEs.  The added irAEs are included in 
Section [IP_ADDRESS].4, Section [IP_ADDRESS], and Section 6.5.2 .9. 
Rational for change:  Updates and/or additions reflect evolving guidance in published 
recommendations.  
5. Incorporation of administrative changes.   Other minor, administrative changes have 
been incorporated throughout the Protocol and are noted in the red line version of the 
amendment.  
Incyte Corporation  Page 89 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Amendment 6 ( [ADDRESS_98105] 2020)  
Overall Rationale for the Amendment:   The primary purpose of this amendment is to increase  
the sample size of the study to allow for more robust characterization of the primary and 
secondary endpoints.  
1. Section 1, Protocol Summary (Table 2 :  Key Study Design Elements); Section 4.1, 
Overall Design; Section 4.2, Overall Study Duration; Section 10.1, Sample Size 
Determination; Section 10.2, Populations for Analysis (Table 22 :  Populatio ns for 
Analysis); Section 10.4, Statistical Analyses; Section [IP_ADDRESS], Overall Response 
Rate; Section [IP_ADDRESS], Duration of Response; Section [IP_ADDRESS], Disease Control Rate ; 
Section [IP_ADDRESS], Progression -Free Survival; Section [IP_ADDRESS], Overall Survival ; 
Section [IP_ADDRESS], Efficacy Endpoints for Full Study Population  
Description of change:   The number of participants to be enrolled was increased  to 
[ADDRESS_98106] been  followed for survival for a minimum of 2 years.   The statistical 
section was also  updated to clarify how the populations will be analyzed for the primary 
and final analyses.  
Rationale for change:   Guidance from a regulatory authority  indicated  that additional 
participants should be enrolled for more robust characterization of durabilit y of response 
and OS.  As of Protocol A mendment  6, approximately [ADDRESS_98107] been enrolled in th is study.  An independent , external DMC has 
reviewed the preliminary safety and efficacy data as part of the futility analysis.  The 
safety profile was as expected for agents of this class , and efficacy exceeded the futility 
threshold.  The DMC has recommended that the study procee d as planned.  Therefore, 
the benefit /risk profile of INCMGA00012 remains  favorable in this population.  
The study will continue until all participants receiving active treatment ha ve been 
followed for at least [ADDRESS_98108] 
characterization of durability of response.  Survival follow -up for a minim um of 2 years 
is likely to provide a durable estimate of OS.  The median OS for patients with metastatic 
MCC treated with avelumab was 20.3 months ( D'Angelo  et al 2019 ).  The median OS in 
patients treated with pembrolizumab was not reached at the time of publication ( Nghiem  
et al 2019 ).  Based on these results, it is reasonable to assume that a minimum of 2 years 
of follow -up will provide a reliable estimate of OS.  
Incyte Corporation  Page 90 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  2. Section 2.1, Background ; Secti on 10.1, Sample Size Determination  
Description of change :  Information about avelumab in MCC was updated to reflect a 
recent publication of more mature data.  
Rationale for change :  To provide updated information to investigators.  Preliminary 
data from the  JAVELIN Merkel [ADDRESS_98109] -line MCC patients 
showed an ORR of 62.1% ( D'Angelo et al 2018 ).  Updated data, presented in 2019, with 
a larger sample size (n  = 116) and follow -up of ≥ 15 months show an ORR of 39.7%  
(D'Angelo et al 2019 ).  As the sample size and power for Study INCMGA 0012 -201 are 
based on the preliminary data from the JAVELIN 200 study and published data on 
pembrolizumab, the updated dat a needed to be taken into account.  
3. Section 4.3.1, Data Monitoring Committee ; Section 10.5, Futility Analysis  
Description of change :  An update on the futility analysis has been provided.  
Rationale for change :  This information was included  to provide infor mation to 
reviewers and investigators regarding the futility analysis . 
 
 
  
 
 
5. Incorporation of administrative changes.   Other minor, admini strative changes have 
been incorporated throughout the Protocol and are noted in the redline version of the 
amendment.  

Incyte Corporation  Page 91 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Amendment 5  (09 APR 2020 ) 
Overall Rationale for the Amendment:   The primary purpose of this amendment is to clarify 
the definition of target lesions for participants who have progression in areas previously treated 
with locoregional therapy.  
1. Section 1, Protocol Summary (Table 1, Primary and Secondary Objectives and 
Endpoints; Table 2, Key Study Design Elements); Section 3, Objectives and  
Endpoints (Table 5: Objectives and Endpoints); Section 4.1, Overall Design; 
Section  5.1, Inclusion Criteria (Criterion 3); Section 5.2, Exclusion Criteria 
(Criterion 1); Section 10.1, Sample Size Determination; Section 10.4.2, Secondary 
Analyses; Section [IP_ADDRESS], Efficacy Endpoints for Full Study Population  
Description of change:   The study design and eligibility criteria were adjusted to 
exclude participants who have received prior systemic therapy for treatment of MCC.  
All relevant sections were update d accordingly.  
Rationale for change:   The treatment landscape for patients with advanced/metastatic 
MCC has changed with the availability of anti –PD-(L)1 therapi[INVESTIGATOR_014].  These therapi[INVESTIGATOR_89167], and it is rare for patients to 
receive systemic che motherapy before treatment with an anti –PD-(L)1 agent.  The 
primary endpoint of this study is ORR in chemotherapy -naive participants with 
advanced/metastatic MCC.  Chemotherapy -refractory patients are becomingly 
increasingly uncommon as demonstrated by [CONTACT_89230] w recruitment in this study.  Only 
5 chemotherapy -refractory participants were enrolled in this study in 18 months.  
Chemotherapy -refractory participants are hence excluded from future enrollment in 
this study.  
2. Section 1, Protocol Summary; Section 4.1, Ove rall Design  
Description of change:   Updated to indicate that t reatment delays of > 12 weeks for 
logistical reasons (eg, travel restrictions due to COVID -19) may be acceptable but must 
be discussed with the medical monitor . 
Rationale for change:   To allow f or continued participation in the study if there are 
treatment delays longer than 12 weeks for certain logistical reasons.  
3. Section 2.2, Study Rationale  
Description of change:   Removed redundant text in the second paragraph.  
Rationale for change : The inform ation is included elsewhere in the section.  
4. Section  5.1, Inclusion Criteria (Criterion 5); Section 8.2.1, Tumor Imaging  
Description of change:  Protocol language was updated to clarify that tumor lesions 
located in areas that have received prior locoregional therapy may be selected as target 
lesions if progression has been demonstrated in these lesions.  
Rationale for change:  In Amendment 4, the Protocol was revised to allow participants 
with recurrent, advanced locoregional MCC to enroll in the s tudy.  Protocol language 
regarding the selection of target lesions in areas subjected to locoregional therapy needed 
to be updated to reflect this change.  
Incyte Corporation  Page 92 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  5. Section 5.2, Exclusion Criteria (Table 6, Exclusionary Laboratory Values)  
Description of change:   Adjusted creatinine clearance value considered exclusionary 
was changed to <  30 mL/min.  
Rationale for change:  Monoclonal antibodies are not filtered by [CONTACT_10521]; therefore, 
the PK of INCMGA00012 should not be impacted by [CONTACT_89231].  No significant drug -related renal toxicity has been 
observed in more than [ADDRESS_98110] used a creatinine clearance of 30 mL/min as threshold for administration.  
6. Section 8.3.6, Laboratory Assessments (Table 19, Required Laboratory Analytes)  
Description of change:  Added free T4 to the list of acceptable analytes.  
Rationale for cha nge:  Either free T4 or total T4 is acceptable for monitoring thyroid 
hormone levels.  
7. Appendix B, Response Evaluation Criteria for Solid Tumors Version 1.1  
Description of change:   Language was updated to reflect RECIST v1.1 terminology.  
Rationale for chang e:  Language in the appendix was not consistent with RECIST v1.[ADDRESS_98111] 
been incorporated throughout the Protocol and are noted in the redline version of the 
amendment.  
Incyte Corporation  Page 93 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Amendment 4 ( 16 AUG 2019)  
Overall Rationale for the Amendment:  
The primary purpose of this amendment is to expand the eligibility criteria to include participants 
with recurrent locoregional advanced disease in addition to participants with  distant  metastatic 
MCC.  
1. Section 1, Protocol Summary; Section 2.1, Background; Section 2.2, Study 
Rationale; Section 3, Objectives and Endpoints; Section 4.1, Overall Design; 
Section  5.1, Inclusion Criteria (Criterion 3)  
Description of change:  Updated to allow pa rticipants with recurrent , advanced  
locoregional MCC to enroll in the trial.  
Rationale for change:   Approximately half of patients with locally advanced MCC 
experience disease recurrence within 2 years from diagnosis.  Management of patients 
with recurrent  locally advanced unresectable MCC is challenging ( Becker JC, Stang A, 
DeCaprio JA, et al. Merkel cell carcinoma.  Nat Rev Dis Primers 2017;3:[ZIP_CODE]. ).  
Similar to distant metastatic disease, patients with recurrent unresectable MCC require 
systemic therapy  to achieve disease control.  While MCC is responsive to chemotherapy, 
the responses are short lived.  Durable responses have been achieved with anti -PD-(L)1 
antibodies in patients with metastatic as w ell as recurrent locally advanced MCC 
(Nghiem P, Bhatia  S, Lipson EJ, et al. Durable tumor regression and overall survival in 
patients with advanced Merkel cell carcinoma receiving pembrolizumab as first -line 
therapy. J Clin Oncol 2019;37:693 -702.;  D'Angelo SP, Russell J, Lebbé C, et al. Efficacy 
and safety of  first-line avelumab treatment in patients with Stage IV metastatic Merkel 
cell carcinoma: a preplanned interim analysis of a clinical trial  [published online ahead of 
print March 22, 2018]. JAMA Oncol doi:10.1001/jamaoncol.2018.0077. ; Kaufman HL, 
Russell J, Hamid O, et al. Avelumab in patient with chemotherapy -refractory metastatic 
Merkel cell carcinoma: a multicenter, single -group, open -label, phase 2 trail. Lancet 
Oncol 2016;17:1374 -1385. ).  A 2019 update to the NCCN guidelines also indicate that 
pembrol izumab may be considered as a treatment option for patients with recurrent 
locally advanced disease ( National Comprehensive Cancer Network. National 
Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Merkel Cell 
Carcinoma Version 2.2019 . 2019. https://www.nccn.org/professionals/physician_gls/  
pdf/mcc.pdf .). 
Patients with recurrent locally advanced disease who are not amenable to definitive 
surgery or radiation are likely to benefit from treatment with anti –PD-1 therapy and 
hence wi ll be eligible for this trial.  
2. Section 1, Protocol Summary; Section 4.1, Overall Design  
Description of change:  Laboratory requirements for subsequent study treatment cycles 
were removed from the Protocol.  
Rationale for change:  Laboratory abnormalities are addr essed in other criteria and do 
not need to be specifically listed as these abnormalities are not expected to worsen with 
immunotherapy.  
Incyte Corporation  Page 94 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL   
 
 
 
4. Section 1, Protocol Summary (Table 4, Pharmacokinetic  Sample 
Collections); Section 8.4, Pharmacokinetic Assessments (Table 20, Pharmacokinetic 
 Serum Blood Sample Timing);  
 
Description of change:  Added tables to detail the timing of PK,  
 
Rationale for change:  To provide clarity to the investigational sites and to remove 
unnecessary blood sampling for study participants.  
5. Section 1, Protocol Summary; Section 10.1, Sample Size Determination; 
Section  10.2, Populations for Analys is; Section [IP_ADDRESS], Overall Response Rate  
Description of change :  The FAS population was updated to include all participants who 
received a dose of study drug.  
Rationale for change :  To address regulatory feedback from the [LOCATION_002] Food and 
Drug Adm inistration.  
  
 
 
 
7. Section 6.5.1, Management of Suspected Infusion Reactions (Table 8 , Guidelines for 
Management of Suspected Infusion Reactions ) 
Description of change:  Updated instruction for subsequent infusions for participants 
who have experienced a Grade 1 infusion reaction.  
Rationale for change:  Premedication is no  longer required per Amendment 2, so 
guidelines for management of suspected infusion reactions were updated to instruct sites 
to consider premedication in participants who experienced Gra de 1 infusion reactions.  
8. Section 6.5.2 .4, Immune -Mediated Endocrinopathies; Section [IP_ADDRESS], 
Immune -Mediated Skin Reactions  
Description of change:   Updates were made to irAE guidance in regard to restarting 
study t reatment.  
Rationale for change:   To make guidance consistent with ASCO  clinical practice 
guidelines.  

Incyte Corporation  Page 95 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  9. Section 6.6.2, Prohibited Medications and Procedures  
Description of change:   Added probiotic dietary supplements to the list of prohibited 
medications.  
Rationale for change:   Updated bas ed on emerging evidence that indicates the use of 
probiotic supplements may be associated with lower chance of responding to  
immunotherapy.  
10. Incorporation of administrative changes.   Other minor, administrative changes have 
been incorporated throughout the Protocol and are noted in the redline version of the 
amendment.  
Incyte Corporation  Page 96 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Amendment 3 ( 05 DEC 2018 ) 
Overall Rationale for the Amendment:  
The primary purpose of this amendment is to address comments received from Health Canada.  
Additional clarifications and administ rative changes were also made.  
1. Section 1, Protocol Summary; Section 4.1, Overall Design; Section 7.1.1, Reasons for 
Discontinuation  
Description of change:  Clarified that participants should be discontinued from study 
treatment for disease progression.  
Rationale for change:  Prior version of the Protocol required participants to discontinue 
from treatment for clinical disease progression; however, in general participants should 
also be removed from study treatment after radiographic disease progression.  
2. Section 1, Protocol Summary (Table 3, Schedule of Activities); Section 8.3.6, 
Laboratory Assessments (Table 19, Required Laboratory Analytes)  
Description of change:   Blood chemistry safety panel no longer specifies that it must be 
from serum.  
Rationale for  change:   To allow convenience for sites who typi[INVESTIGATOR_89168].  
3. Section 1, Protocol Summary (Table 3, Schedule of Activities); Section 5.2, 
Exclusion Criteria; Section 6.6.1, Permitted Medications and Procedures; 
Section  8.3.6,  Laboratory Assessments (including Table 19, Required Laboratory 
Analytes)  
Description of change:  Participants who are HIV -positive may be enrolled into the 
study provided they meet the criteria specified in exclusion criterion 21.  For those 
HIV-positive  participants who do enroll, HIV management testing will be required and is 
now detailed in the Protocol.  
Rationale for change:  To allow inclusion of participants with well -controlled HIV in 
this study since preliminary experience with immunotherapy in HI V-associated 
malignancy is promising.  
 
 
 
 
 
 

Incyte Corporation  Page 97 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  5. Section 1, Protocol Summary (Table 3, Schedule of Activities); Section 4.1, Overall 
Design; Section 8.8.1, Safety Follow -Up 
Description of change:   Clarified  that AEs and concomitant medicati ons are to be 
collected for [ADDRESS_98112] dose of study drug or until the participants start a new 
anticancer therapy.  
Rationale for change:  Editorial change to ensure consistency with Sections 6.6, 8.3, and 
9.4 in the Protocol.  
 
 
 
 
 
 
 
 
 
 
7. Section 1, Protocol Summary (Table 1); Section 3, Objectives and Endpoints 
(Table 5); Section 6.5.1, Management of Suspected Infusion Reactions (Table 8); 
Section 8.3.1, Adverse Events; Section 9.3, Recording and Follow -Up of Adverse 
Events and/or Serious Adverse Events  
Description of change:  Updated Protocol to indicate that CTCA E v5.0 will be used to 
assess the severity of AE.  
Rationale for change:  To use the most recent version of CTCAE.  
8. Section 1, Protocol Summary (Table 3, Schedule of Activities)  
Description of change:  Added note indicating that survival status may be reques ted at 
any point during the study.  
Rationale for change:   To allow flexibility for collecting updated survival data for 
analysis if required.  
9. Section 1, Protocol Summary (Table 3, Schedule of Activities; Table 4, 
Pharmacokinetic  Sample Collections)  
Description of change:   Adjusted the window for subsequent cycle visits to 7 days.  
Rationale for change:   To allow flexibility for participant scheduling.  
10. Section 2.2, Study Rationale  
Description of change:  Results from the first -in-human mon otherapy study (INCMGA 
0012 -101) were updated.  
Rationale for change:  Provide updated information to investigators.  

Incyte Corporation  Page 98 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  11. Section 5.2, Exclusion Criteria  
Description of change:   The ALT and AST exclusionary laboratory values were adjusted 
to allow for the possibility of participants with liver metastases to enroll if their ALT or 
AST are ≤ 5 × ULN.  
Rationale for change:  Language in prior versions of the Protocol had strict excl usion 
criterion for ALT and AST that may have excluded participants with liver metastases that 
were otherwise good candidates for the study.  
12. Section 6.1, Study Treatment Administered (Table 7, Study Treatment 
Information); Section 6.5.1, Management of Susp ected Infusion Reactions; 
Section  6.6.1, Permitted Medications and Procedures  
Description of change:  Removed the requirement for premedication prophylaxis before 
the first dose of INCMGA00012.  
Rationale for change:  Updated for consistency with the INCMGA [ZIP_CODE] IB.  
13. Section 6.5.1, Management of Suspected Infusion Reactions (Table 8, Guidelines for 
Management of Suspected Infusion Reactions)  
Description of change:   Additional guidance on the rate of infusion after a suspected 
infusion reaction was provided.  
Rationale for change:   To provide clarification to sites.  
14. Section 7.1.1, Reasons for Discontinuation  
Description of change:  Added language that allows participants to discontinue study 
treatment if they achieve a confirmed CR and have received at least 6  months of study 
treatment.  
Rationale for change:  This change will allow flexibility for the investigator to decide if 
it is in the participant's best interest to discontinue study treatment after achieving a CR.  
  
 
. 
 
 
16. Section 8.3.3, Vital Signs  
Description of change:  Language was added to provide guidance on timing of vital 
signs in regards to blood collection when it is not feasible for vital signs to be taken 
before the blood collection.  
Rationale for change:  This language was added to allow flexibility for sites in 
scheduling procedures . 

Incyte Corporation  Page 99 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  17. Section 8.3.5, Electrocardiograms  
Description of change :  Additional information was provided regarding the timing of 
ECGs and the need for triplicate ECGs.  
Rationale for change:   To provide additional information to the sites.  
18. Section 9.7, Pregnancy  
Description of change:  Updated the time frame for restarting study treatment to 
12 weeks.  
Rationale for change:  To make the time frame consistent with treatment interruptions 
for other reasons.  
19. Incorporation of administrative changes:   Other minor administr ative changes have 
been incorporated throughout the Protocol and are noted in the redline version of the 
document.  
Incyte Corporation  Page 100 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Amendment 2 ( [ADDRESS_98113] 2018)  
Overall Rationale for the Amendment:  
The primary purpose of this amendment is to address comments received from the  European 
Competent Authorities during the  VHP.  
1. Section 1, Protocol Summary; Section 4.1, Overall Design  
Description of change:  Prior to receiving infusion of INCMGA00012, participants must 
have a hemoglobin level of ≥ 9 g/dL.  
Rationale for change:   This requirement was changed based on feedback from the 
European Competent Authorities during the VHP and is consistent with the eligibility 
criterion for the study regarding hemoglobin.  
2. Section 1, Protocol Summary; Section 4.1, Overall Design; Section 6.5, Do se 
Modifications  
Description of change:  Edits were made to clarify that study treatment doses will not be 
modified, but dosing can be interrupted up to 12 weeks prior to restarting.  
Rationale for change:  Provide additional clarity to clinical sites.  
3. Section 1, Protocol Summary; Section 4.3, Study Termination; Section 4.3.1, Data 
Monitoring Committee; Section 10.5, Futility Analysis  
Description of change:   An independent data monitoring committee will be formed.  
Rationale for change:   To provide indepe ndent review of safety and efficacy data during 
the study.  
4. Section 1, Protocol Summary (Table 3, Schedule of Activities); Section 6.1, Study 
Treatment Administered (Table 7, Study Treatment Information)  
Description of change:  A note was added to Table 3 a nd Table 7 to remind sites to 
monitor for reactions during the infusion of INCMGA00012.  
Rationale for change:  To make it clear in the Protocol that sites should be monitoring 
participants for infusion reactions per their institutional guidelines during th e infusion 
period.  
5. Section 2.2, Study Rationale  
Description of change:  Background information for INCMGA00012 was added to the 
Protocol.  
Rationale for change:  This language will provide updated  safety  information regarding 
the study treatment to investig ators.   
Incyte Corporation  Page 101 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  6. Section 5.1, Inclusion Criteria;  Section 5.2, Exclusion Criteria;  Section 6.6.2, 
Prohibited Medications and Procedures  
Description of changes:  
• Inclusion Criterion 7b:  The duration of contraception for females was changed to 
[ADDRESS_98114] dose of study treatment.   
• Exclusion Criterion 13:  The criterion was edited to exclude participants who have 
received a live virus vaccine within 28 days of the start of study therapy.  The 
protocol previously used a 90 -day timeframe p rior to the start of study therapy.  This 
timeframe was updated in the prohibited medications and procedures section as well 
for consistency.  
• Exclusion Criterion 19:  This new criterion was added to exclude anyone with a 
history of organ transplant , includ ing allogeneic stem cell transplantation.  
• Exclusion Criterion 20:  This new criterion was added to exclude anyone  with a 
known allergy or hypersensitivity  to any component of the study drug formulation.  
Rationale for changes:   Inclusion/exclusion criteria were update d to address  
inconsistencies and address comments from European Competent Authorities during the 
VHP . 
7. Section 5.5, Replacement of Participants  
Description of change:  Additional clarity was provided on how participants may be 
replaced if they do  not meet eligibility criteria.  
Rationale for change:  Provide additional clarif ication  to clinical sites.  
8. Section 6.5.1, Management of Suspected Infusion Reactions (Table 8:  Guidelines for 
Management of Suspected Infusion Reactions)  
Description of change :  Table [ADDRESS_98115] be 
discontinued for any ≥ Grade 3 infusion -related reaction.  The definition of a Grade  3 
infusion reaction was also edited to match CTCAE guidance.  
Rationale for change:  Guidance for infusion -related reactions was edited to provide 
additional clarity to clinical sites .   
9. Section [IP_ADDRESS], Immune -Mediated Myocarditis  
Description of change:  Guidance for the management of immune -mediated myocarditis 
was added.   
Rationale for change:   These events can be serious , and therefore , it is prudent to 
provide guidance to the Investigators.  
10. Section 7.1.1, Reasons for Discontinuation  
Description of change:  Pregnancy was listed as a reason for discontinuation from study 
treatment.  
Rationale for change:  Prov ide additional clarification to clinical sites . 
Incyte Corporation  Page 102 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  11. Section 8.2, Efficacy Assessments; Section 8.2.1, Tumor Imaging  
Description of change:   Language was added to specify that disease status will be 
evaluated by [CONTACT_89232] (ICR).   
Rationale for change:  The Protocol was not clear that the response assessments will be 
performed by [CONTACT_89233].  
Incyte Corporation  Page 103 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  Amendment 1 ( 27 JUN 2018)  
Overall Rationale for the Amendment:  
The primary purpose of this amendment is to address comment s received from the US FDA.  
1. Section 1, Protocol Summary (Table 1 :  Primary and Secondary Objectives and 
Endpoints ); Section 3, Objectives and Endpoints  (Table 5 :  Objectives and 
Endpoints ), Section 4.1, Overall Design  
Description of change s: 
• Assessment of the primary endpoint of ORR will be limited to the  chemotherapy -
naive study population .  The ORR in the full study population , comprised of both 
chemotherapy -naive and chemotherapy -refractory participants, will be a ssessed as a 
secondary endpoint.  
• Multiple  secondary endpoints have been added and/or revised to specify that the 
analysis will be performed on the chemotherapy -naive population and the full study 
population, comprised of both chemotherapy -naive and chemotherapy -refractory 
participants.  
Rationale for change s: 
• The primary efficacy assessment should be performed in a homogeneous population 
(per guidance  from the FDA ), since a higher ORR is expected in the 
chemotherapy -naive population based on emerging data.  
• The primary endpoint of the study has been  revised and is now based only on the 
chemotherapy -naive population.  Therefore, the secondary efficacy analysis has been 
revised and will include analysis of the full study population.  
2. Section 1, Protocol Summary; Section 4.1, Overall Design  
Description o f change s: 
• The following language was added to the description of study participants:  "The 
participants should not have received any prior therapy with PD -1/PD -L1 inhibitors ." 
• The criteria for eligibility for subsequent treatment cycles was updated to address the 
maximum allowable length of time for delaying study drug treatment.  
Rationale for change s: 
• The added language regarding prior therapy with PD -1/PD -L1 inhibitors is intended 
to provide c larification of the study population . 
• The revised  language regarding criteria for eligibility for subsequent treatment cycles 
provides further definition and clarification of the treatment criteria for subsequent 
cycles and the maximum length of time a participant can be on a drug hold before 
being permanently dis continued from study treatment.  
Incyte Corporation  Page 104 of 104 
Protocol INCMGA 0012 -201 Am 7  Version 7  16 DEC 2021  
VV-CLIN -000630  CONFIDENTIAL  3. Section 5 .1, Inclusion Criteria  
Description of change:   Eligibility criterion #3 was modified to clarify  that that the 
study population will be limited to participants with distant, metastatic disease.  
Rationale for change:   This language is intended to clarify, as  this study excludes 
participants with loco regional disease.  
4. Section 1, Protocol Summary; Section  10.1, Sample Size Determination ; 
Section  10.4, Statistical Analyses  
Description of change:   Assumptions and sample s ize were revised  in accordance with 
literature estimates for ORR in both the primary effic acy population (chemotherapy -
naive) and the full study population of chemotherapy -naive and chemotherapy -refractory 
patients.  Final sample size also reflects allowan ce for attrition during the cou rse of the 
study.   Statistical analyses were updated to align with the revised primary and secondary 
efficacy endpoints.  
Rationale for change:   Alignment with revised primary  and secondary  efficacy 
objectives and endpoint s. 
The recent availability of avelumab, in many countries for frontline treatment of 
metastatic MCC, has impacted practice patterns.  While both chemotherapy and 
checkpoint inhibitor therapy may be appropriate for initial treatment based on practice 
guideline s (as per the NCCN) and local reimbursement policies, it is expected that, over 
the duration of the study, an increasing majority of participants will be offered 
checkpoint inhibitors as frontline therapy.  Therefore, a small excess of chemotherapy -
naive p articipants (55%) has been assumed for the projected enrollment in calculating 
the expected ORR for the full study population.  
5. Section 10.5, Futility Analysis  
Description of change:   Language was revised to indicate that the f utility analysis will 
be based on responses in the chemotherapy -naive population.  The number of participants 
assessable for response needed for the analysis was updated from 25 to 20.  
Rationale for change:   Alignment with revised primary objective and endpoint.  
Incorporat ion of administrative changes.   Other minor, administrative changes have 
been incorporated throughout  the Protocol and are noted in the redline version of the 
amendment.  
Signature [CONTACT_11032]-CLIN-000630 v9.0
Signature [CONTACT_11032]-CLIN-000630 v9.0Approval
16-Dec-2021 15:28:42 GMT[PHONE_006]
Approval
16-Dec-2021 15:41:35 GMT[PHONE_006]
Approval
17-Dec-2021 03:02:40 GMT[PHONE_006]
Approval
17-Dec-2021 08:09:51 GMT[PHONE_006]
